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Abstract 
Astrocytic tumors are the most common primary intracranial neoplasm, 
accounting for 25 — 35% of all primary brain tumors. Despite successful local 
control by modern surgical techniques, challenges remain with the eradication of 
infiltrating tumor cells. Even low-grade diffuse astrocytoma has an intrinsic 
tendency to progress to higher-grade tumors. Molecular understanding of tumor 
pathogenesis would be important for drawing up more accurate diagnostic criteria, 
prognosis and development of new treatment strategies. 
Recently, activating mutation of BRAF was discovered in a wide variety of 
cancers, with T1796A substitution leading to V599E amino acid change 
representing 80% of all mutations identified. The first aim of my study is to 
investigate whether BRAF alteration is involved in CNS tumors. I performed 
direct cycle sequencing on exons 11 and 15 of the BRAF gene to evaluate the 
frequency of BRAF mutation in a tumor series comprising of 23 diffuse 
astrocytomas, 18 AAs, 53 GBMs (including 2 gliosarcomas), 31 oligodendroglial 
tumors, 23 ependymal tumors, 21 medulloblastomas and 26 meningeal tumors, 
and 10 cell lines including six from astrocytic tumors, three from 
medulloblastomas and one from primitive neuroectodermal tumor. I also 
examined the expression of B-Raf by immunohistochemistry in 25 GBMs, 13 
AAS and 9 diffuse astrocytomas. Since EGFR, the upstream activator of Raf 
proteins, is frequently amplified (50%) in primary GBM, EGFR gene dosage of 
astrocytic tumors was investigated for correlation analysis between EGFR 
amplification and BRAF alterations. 
iii 
Heterozygous BRAF^e mutation was revealed in one GBM specimen and 2 
GBM cell lines (GBM2603 and GBM6840). Results of sequence 
electropherograms and karyotyping suggest gain of mutant gene copies in the 2 
cell lines. Hence, both sequence alteration and enhanced copy number of mutant 
BRAF allele are involved in the development of GBM. Furthermore, B-Raf 
expression was detected in approximately 30% of astrocytic tumors but not in 
normal astrocytes from 10 brain autopsies. Higher expression of B-Raf in 
astrocytic tumors than in normal astrocytes pointed to possible functional changes 
in favor of tumorigenesis. Also, B-Raf immunoreactivity was detected in all 
tumor grades. Abnormal expression of wild-type B-Raf protein in the low-grade 
diffuse astrocytoma suggests that BRAF alteration is an early event in 
tumorigenesis of astrocytic tumors. Analysis of 30 astrocytic tumors showed 
mutually exclusively pattern ofEGFR amplification and B-Raf immunoreactivity. 
Activation of the wild-type B-Raf proteins might require autocrine signaling. 
Taken together, my data demonstrated that BRAF is altered at the genomic and 
proteomic level, suggesting that BRAF plays an important role in the 
tumorigenesis of a proportion of astrocytic tumors. 
In the second part of my thesis, I carried out deletion mapping of chromosome 
14q in astrocytic tumors. Our group has previously performed a genome-wide 
microsatellite analysis and detected two common regions of deletion (CRDs) on 
14q21.2 — q23.12 and 14q32.1 — qter in 50% GBM and 35% AA. These data 
suggest that chromosome 14q may contain a putative tumor suppressor and its 
inactivation may contribute to the development of astrocytic tumors. To refine 
iv 
CRD in 14q21.2 — q23.12 in astrocytic tumors, 18 microsatellite markers were 
used to analyze the allelic status in 14q of 15 GBMs (including 2 gliosarcomas), 5 
AAs and 12 diffuse astrocytoma. Mapping ofLOH loci revealed 4 CRDs locating 
in 14q23.1 — q23.2 (CRDl, D14S592 to D14sl026)，14q24.1 — q24.2 (CRD2, 
D14S1011 toD14S77), 14q24.3 (CRD3, D14S43 toD14s59)and 14q31.1 - q31.3 
(CRD4, D14S1000 to D14S68), spanning 3.3, 4.0, 3.2 and 6.5 Mb，respectively. 
All of them overlap with those of other tumor types, such as renal cell carcinoma 
and neuroblastoma. Based on fiinctional implications from other isoforms or 
alterations in other cancers, PPP2R5E and MLH3 were identified as putative 
tumor suppressor genes worth further characterization. Nevertheless, the 4 CRDs 
are still considerably too large for positional cloning of candidate genes. Further 












































14q2L 2 - q23. 12區域進行更爲精細的DNA微衛星檢測’本硏究應 
用了 18對微衛星標志來分析13例GBM (包括例神經膠質肉瘤）、5 
例AA和12例彌散型星形膠質瘤的等位基因雜合子丟失狀況。雜合 
子丟失圖顯示了 4個更精細的 C R D ,分別爲 1 4 q 2 3 . 1 - q23. 2 
(CRDl， D14S592 - D14S1026)、14q24. 1 - q24. 2 (CRD2， 
D14S1011 - D14S77)、14q24. 3(CRD3 ’ D14S43 - D14S59)以及 
14q3L 1 - q31.3(CRD4，D14S1000 - D14S68)，丟失片段的序列範 
圍分別爲3. 3、4. 0、3. 2及 6 . 5 Mb。這些丟失片段與其它的腫瘤的 
共同丟失片段有重疊’例如腎細胞癌、神經母細胞腫瘤。基於其它 
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1. Introduction 
L1. What are astrocytic tumors? 
The central nervous system (CNS) comprises mainly of neurons and glial 
cells. Astrocytes make up a main category of glial cells and are responsible for 
regulating neuronal growth and survival, guiding cell migration and axon growth 
during development, promoting synapse formation and modulating synaptic 
transmission, and orchestrating inflammatory and immune responses during brain 
infection and injury (Wechsler-Reya and Scott, 2001). 
Gliomas comprise of tumor cells resembling glial cells. Similarly, astrocytic 
tumors are those with histological appearances of astrocytes (Louis et a/., 2001; 
Maher et al., 2001). Diffusely infiltrating astrocytic tumors will be the focus of 
this study. 'Astrocytic tumors' in the current study referred to the diffusely 
infiltrating astrocytic tumors of all grades. Non-infiltrating variants, including 
pilocytic astrocytoma, pleomorphic xanthoastrocytoma, desmoplastic cerebral 
astrocytoma of infancy and subependymal giant cell astrocytoma, are out of the 
scope of the present study. 
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1.1.1. Histological characteristics and classification 
Astrocytic tumors are classified by the World Health Organization (WHO) 
into three grades and can also be practically designated by St. Anne/Mayo's four 
criteria (Kleihues and Gavennee, 2000). Diffuse astrocytoma is designated into 
grade II with one criterion, usually nuclear atypia. Anaplastic astrocytoma (AA), 
characterized by two criteria, usually mitotic activity and nuclear atypia, is 
designated into grade III. Glioblastoma multiforme (GBM) is designated into 
grade IV with the presence of endothelial proliferation and/or necrosis, in addition 
to mitotic activity and nuclear atypia. 
As indicated by the term multiforme, GBM is heterogeneous in terms of 
tumor morphology and behavior (Wechsler-Reya and Scott, 2001). It is 
subdivided into de novo (primary) and secondary ones, based on different 
progression kinetics (Section 1.1.2). 
1.1.2. Epidemiology 
The astrocytic tumors are the most common primary intracranial neoplasms. 
In United States of America (U.S.A.), GBM, AA and diffuse astrocytoma 
respectively represented 23%, 3.9% and 6% of all primary brain tumors and 
occurred at 2.96，0.49 and 0.13 per 100,000 persons during 2000 (Central Brain 
Tumor Registry of the United States, 2000). In Hong Kong, they represented 
2 
15%, 6.5% and 3.6% respectively from 1984 to 1987 (Ng et al.’ 1988). In 
Singapore, astrocytic tumors account for a total of 25% of primary brain tumors 
(Das et al., 2002). In China, gliomas account for 40% of primary CNS tumors 
(Poon and Ng, 1992). Ethnically, age-adjusted rates for GBM in U.S.A. were 2.5 
times higher in whites than in blacks in 1990 - 1994 (Central Brain Tumor 
Registry of the United States, 2000). 
Astrocytic tumors usually manifest in adults with a male predominance based 
on biopsies of 1914 patients from the Tumor Registry of the University of 
California and the Institute of Neuropathology of University Hospital, Zurich. 
Peak incidence of diffuse astrocytoma lies in 30 - 40 years with a male/female 
ratio of 1.18:1. The male/female ratios become 1.8:1 in AA and 1.5:1 in GBM 
(Zulch, 1986). 
In general, peak incidence of GBM lies in 45 — 70 years. The majority of 
GBM develop rapidly with a short clinical history and with no clinical or 
histological evidence of a less malignant precursor lesion. They manifest in a 
higher age group with a mean at 55 years and are termed de no or primary GBM. 
Other GBM, which develop slower and carry a history of development from 
lower-grade lesions are called secondary GBM. They manifest in a mean age of 
40 years and cannot be distinguished histologically from primary ones (Kleihues 
and Ohgaki, 1999). 
3 
Astrocytic tumors may arise at any site in the CNS, preferentially in the 
cerebral hemisphere. The frontal and temporal lobes are the most frequently 
affected locations. Combined fronto-temporal location is particularly typical in 
GBM. Tumor infiltration often extends into the adjacent cortex, the basal ganglia 
and the contralateral hemisphere. 
1.1.3. Treatment and patient survival 
Treatment of diffuse astrocytoma mostly aims at gross total resection for 
longer relapse-free survival. For deep or diffuse lesions, conventional fractionated 
radiation via regional fields to a dose of at least 50 Gy usually follows stereotactic 
biopsy. Post-surgery radiation therapy has been significantly better than those for 
the surgery-alone, where sex, tumor site, extent of surgery, radiation dose and 
field, and adjuvant chemotherapy do not influence the prognosis significantly 
(Shibamoto et al., 1993). A course of observation might be taken with close 
monitoring of neurological assessment and magnetic resonance imaging. 
However, most clinicians recommend treatment when confronted with a patient 
with any of these clinical or imaging features. 
The literature on survival of patients with diffuse astrocytoma consists 
predominantly of retrospective reviews sometimes not well controlled. Criteria 
for selection of patients to various treatment regimens are not specified. This 
4 
leads to controversy in comparison of different treatment strategies. However, the 
major cause of mortality for a patient with diffuse astrocytoma results form 
transformation to higher-grade lesions, regardless of the treatment selected. The 
median survival time of diffuse astrocytoma after surgical intervention is in the 
range of 6 - 8 years, with marked variation (Walker and Kaye, 2001). 
Surgical resection is effective in prolonging survival for selected patients and 
improving the quality of life for many patients. Without treatment, 95% of 
patients with GBM die within 3 months. Radiation therapy also increases long-
term survival of patients with high-grade glioma, especially those younger than 65 
years. Moreover, marginal survival advantage in treatment of AA and GBM has 
been provided by chemotherapy, along with surgical resection and post-operative 
radiation therapy. Typical survivals of AA and GBM are extended to 2 - 5 years 
and 1 — 2 years, respectively (Louis et al.’ 2001). 
Modern microsurgical techniques and excellent post-operative care have been 
successful in local control of the lesions. Challenges lie on the eradication of cells 
that have already infiltrated into functioning parenchyma. Molecular biology 
techniques involving gene therapy that attacks regulation mechanisms of 
proliferation and abnormal cellular survival are the promising area for modern 
research. 
5 
1,2. Cytogenetics, molecular genetics and epigenetics of astrocytic tumors 
The relation of cancer to genetics can be traced back to 1914. Prompted by 
von Hansemann's observations of aberrant mitoses, Boveri (1914) predicted the 
presence of oncogenes and tumor suppressor genes (TSGs). The discovery of 
mutagenic effect of ionizing radiation and other carcinogens then related somatic 
mutation to cancer. Nowadays, tumor progression is widely regarded as the result 
of sequential accumulation of genetic abnormalities. 
Knudson's 'two-hit' hypothesis had been used initially to describe hereditary 
tumors caused by somatic mutation of one allele of a TSG in addition to a 
germline mutation in the other allele. In considering tumor progression as a 
multi-step process, the theory of mutations in two alleles of TSG has been 
expanded to include at least loss/deletions and gene silencing by methylation and 
the combination of them (Knudson, 2001; Tomlinson et al.’ 2001; Tucker and 
Friedman, 2002). 
1.2.1. Cytogenetics 
Among early cytogenetic studies, the majority of diffuse astrocytomas is 
characterized by a normal karyotype or simple numerical changes, in particular 
trisomy 7, monosomy 10 and 22, or loss of a gonosome. On the other hand, some 
AA and most GBM displayed highly complex karyotypes. In addition to frequent 
6 
trisomy 7, monosomy 10 and 22, partial deletions on 9p and 17p were also 
revealed. Other observations include changes in the ploidy range and 
chromosomal rearrangements involving in particular chromosomes 1 and 9, and 
double-minute chromosomes associated with amplification of the epidermal 
growth factor (EGFR) gene (Debiec-Rychter et al, 1995; Schrock et al, 1994; 
Vagner-Capodano, 1991). 
The accumulation of chromosomal changes in increasing grades of astrocytic 
tumors was often seen. However, traditional cytogenetic analysis of brain tumors 
had been difficult due to difficulties in primary cultures of low-grade tumors, 
selection bias in cells being analyzed and the complexity of chromosomal 
abnormalities (Teyssier, 1987 and 1989). 
1.2.2. Genetic imbalances 
Comparative genomic hybridization (CGH), a modified fluorescence in situ 
hybridization (FISH) technique introduced in 1992, allows the generation of a 
copy number karyotype of the whole genome (Kallioniemi et al., 1992). Tumor 
DNA and reference DNA from a normal individual are differentially labeled, 
mixed together in equal amounts and co-hybridized under conditions of in situ 
suppression hybridization to normal metaphase chromosomes. Chromosomal 
gains and losses as well as amplifications are mapped along normal metaphase 
7 
chromosomes in a single hybridization. Results from different samples can be 
clearly summarized by plotting the absolute frequency of cases with gains or 
losses at the respective band against consecutively arranged chromosomes, each 
from the telomere of short arm to the telomere of long arm. 
To summarize all major chromosomal abnormalities detected among different 
CGH studies, results were extracted from studies of Brunner et al. (2000)， 
Mohapatra et al. (1998), Nishizaki et al (1998) and Sallinen et al. (1997; Table 
1.1). The major gains and/or amplifications in GBM lie in chromosomes Ip, 7p, 
7q, 12q, 19p and 20q, while losses and/or deletions involve chromosomes 9p, 10 
and 13q. Among these chromosomal abnormalities, gain or amplification of 
chromosome 7 and loss of 9p and 13q are present also in AA, while gain or 
amplification of Ip, 12q and 20q are detectable in diffuse astrocytoma. 
The number of chromosomal aberrations in astrocytic tumors increases with 
tumor grade (Nishizaki et al, 1998). In search for differential patterns of 
chromosomal abnormalities among gliomas form CGH results, the correlation 
between the average number of copy alterations per patient and malignancy for 
astrocytic tumors were confirmed in 26 reports between 1992 and 2001 (Koschny 
et al., 2002). The larger number of abnormalities in high-grade tumors supports 














































































































































































































































































































































































































The number of chromosomal losses in diffuse astrocytoma with poor 
prognosis is very similar to those in AA and GBM and cell lines. In Sallinen et 
al.'s study (1997), chromosomal abnormalities ranged from 0 to 4 in diffuse 
astrocytomas with typical (n = 1) prognosis and 8 to 28 in diffuse astrocytomas 
with poor (n = 4) prognosis, indicating the association of number of aberrations 
with poor prognosis in diffuse astrocytoma. Since the number of samples 
included is rather small, fiirther studies on chromosomal abnormalities in relation 
to prognosis are required. 
Other genome-wide genetic studies, based on relative fragment length 
polymorphism, were brought about along the development of polymerase chain 
reaction (PCR) technique. PGR products from polymorphic microsatellite 
markers on each arm of every human autosome were resolved by electrophoresis 
and subject to relative quantification (Fults et al.’ 1990). Although PCR products 
with different sizes were amplified with different efficiencies, such differences 
could be normalized by simultaneous analysis of normal DNA from the same 
patient. Imbalanced amount of tumor alleles after normalization suggests loss of 
one of the alleles in the tumor, and is described as loss of heterozygosity (LOH). 
Such whole genome analysis of allelic imbalances is called allelotyping. 
10 
A comprehensive allelotyping of nervous system tumors was performed using 
129 microsatellite markers throughout the genome (Von Deimling et al‘, 2000). 
Although some deletion regions were detected in high-grade but not in lower-
grade tumors by CGH, allelotyping revealed LOH in the same regions in all 
tumors grades, for example LOH in 9p (Table 1.2). Other than confirming the 
losses in 9p, lOp, lOq, 13q as detected by CGH, the most frequent LOH regions in 
astrocytic tumors were also located to 17p, 19q and 22q. 
Table 1.2. Major chromosomal abnormalities detected in astrocytic tumors by 
loss of heterozygosity analysis (Von Deimling et al., 2000). 
Diffuse Anaplastic Glioblastoma 
Chromosome astrocytoma astrocytoma multiforme 
{n 二 2 8 ) {n = 3 3 ) {n = 9 0 ) 
% % % 
^ 8 14 Ye 
lOp 10 12 67 
lOq 0 14 75 
13q 0 25 27 
17p 42 55 28 
19q 23 42 30 
22q 9 30 24 
11 
Allelotyping is more sensitive than CGH, probably due to higher-resolution 
mapping. However, it cannot replace CGH studies because amplification of one 
of the alleles or abnormal number of chromosome copies could also lead to allelic 
imbalances. 
Deletions of chromosomes 9p, lOp, 17p, 19q and 22q LOH were detected by 
CGH and/or allelotyping in all three grades of astrocytic tumors. This suggests 
the harboring of early tumor-related genes in these chromosomal arms. In 
contrast, LOH in the long arm of chromosome 10 and 13, and gain or 
amplification in chromosome 7 were detected in AA and GBM but not in diffuse 
astrocytoma, suggesting that the chromosomes carry late genes involved in 
astrocytic tumorigenesis. 
Loss in chromosome lOq and gain in chromosome 19q are associated with 
aggressive clinical behavior in GBM, as revealed by short-term survival, 
particularly when two are present together. On the contrary, loss of 19q may be a 
marker of long-term survivors (Burton et al., 2002). 
In addition to the above chromosomal imbalances, our group members also 
detected loss in 14q in 35% (6/17) of diffuse astrocytoma and 50% (10/21) of 
GBM by high-resolution genome-wide allelotype analysis. Two common regions 
of deletion (CRDs) were mapped to 14q22.3 — q32.1 (recently updated to 
14q21.2 — q32.12 by the human genome project) and 14q32.1 - qter (Hu et al, 
12 
2002). Loss in 14q is related to poor prognosis. While one of two diffuse 
astrocytomas with loss in 14q recurred as GBM at 18 months and led to death at 
28 months, the other died at 19 months after diagnosis (Sallinen et al., 1997). 
1.2.3. Tumor suppressor genes 
Diffusely infiltrating low-grade astrocytomas have an intrinsic tendency for 
progression to AA and GBM. This change is due to sequential acquisition of 
genetic abnormalities, which include loss of TSG activities and gain of oncogene 
activities. On the basis of Knudson's 'two-hit' hypothesis for TSG inactivation, 
detection of a high LOH frequency in a chromosomal region is considered critical 
for TSG localization. LOH is used as a tool for finer deletion mapping of aberrant 
chromosomes after genome-wide analysis for gross aberrations. Tumor protein 
p53 (TP53), phosphatase and tensin homolog (PTEN), retinoblastoma (RB), 
p i 6腦A , p i 严 are the current confirmed TSGs identified in astrocytic tumors. 
Tumor vrotein v53 (TP53) 
The TP53 gene at locus 17pl3.1 encodes p53 that acts as the guardian of the 
genome by mediating either apoptosis or cell cycle arrest in response to DNA 
damage. Cell death induced through the p53 pathway is executed by the caspase 
proteinases, by which cleaving of substrates leads to the characteristic apoptotic 
13 
phenotype (Schuler and Green, 2001). One of the transcriptional targets of p53 is 
p2J 腳】which encodes an inhibitor of the cyclin-dependent kinases (Cdks) in 
both the G1 and G2/M phases of the cell cycle. The p53-mediated cell cycle 
arrest is reversible so as to allow DNA to be repaired before inadvertent 
replication of damaged DNA (Agarwal et al., 1995; Lundberg and Weinberg, 
1999). Loss of function in TP53 is suggested as a cause of genomic instability 
(Nozaki et al, 1999). 
Loss of 17p was detected in high frequency in all three grades of astrocytic 
tumors. In screening of every 2P55-coding exon of 25 GBMs, 14 AAs and 6 
diffuse astrocytomas for somatic mutation by single strand conformation 
polymorphism (SSCP)，approximately 60% of TP53 mutation was found among 
samples with 17p LOH and confirmed by sequencing (Fults et al.’ 1992). Similar 
mutation frequency was also obtained in 14 AAs and 8 diffuse astrocytomas by 
screening only exons 5, 6，1, and 8, the conserved regions of TP53 (Von Deimling 
et al., 2000). Since two-hit of TP53 was detected in all grades, recessive 
mechanism of action of p53 is regarded as an early event. 
Exogenous p53 suppressed growth of astrocytic tumor cell lines (LNZ308 and 
T98G) carrying endogenous mutant or null TP53 alleles (Van Meir et al, 1995). 
Such decrease in tumor growth could be attributed to either apoptosis or cell cycle 
arrest, depending on the expression of (Section 1.3.1). 
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In an attempt to clarify whether the mutation affects sensitivity to therapy and 
prognosis, the locus of TP53 mutation in relation to tumor grade was examined. 
In consideration of the overall TP53 mutation，significant difference was not 
found between AA and GBM. However, a significant difference (P = 0.01) 
between the frequencies of mutation was found in exon 8 between AA and GBM 
(Shiraishi et cd., 2002). Therefore, not only do TP53 mutations contribute to 
tumorigenesis by genomic instability, it also contribute in progression to 
malignancy. 
While exon 8 of TP53 is associated with tumor progression, mutations in exon 
4 occur in 42% (n 二 12) of GBM (Li et al, 1998). Whether this mutation is 
associated with a particular poor prognosis, as in breast carcinoma, await farther 
studies (Powell et al�2000). 
Frequency of TP53 mutation within primary GBM has been controversial. 
However, TP53 mutation is generally less frequent in GBM than AA, suggesting 
that TP53 alteration in primary GBM might not be as common as in secondary 
GBM. Frequency of TP53 mutation in primary GBM (12%, 2/17) is significantly 
lower than that in secondary GBM (85%, 11/13; P = 0.0001) Fujisawa et al., 
2000). 
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Phosphatase and tensin homolos (PTEN) 
The PTEN gene is located on chromosome 10q23.3 and encodes a dual-
specificity phosphatase that recognizes phosphatidylinositol-3,4,5-triphosphate 
(PtdIns-3,4,5-P3) and protein substrates. PTEN acts against phosphatidylinositol-
3-kinase (PI3K) by dephosphorylating PtdIns-3，4,5-P3, which is required for the 
phosphorylation and activation of v-akt murine thymoma viral oncogene homolog 
(Akt), a serine/threonine kinase involved in cell growth and survival. PTEN 
enables G1 arrest by recruiting into the cyclin E-Cdk2 complex and 
inhibiting Cdk2 kinase activity without affecting cyclin E or expression. 
PTEN is also implicated in cell migration and spreading depending on its lipid 
phosphatase activity (Simpson and Parsons, 2001; Tamura et al., 1999; Weng et 
al., 2001). 
GBM cells with mutant PTEN expression contain high endogenous Akt 
activity and high levels of PtdIns-3,4,5-P3 and PtdIns-3,4-P2, the levels of which 
could be reduced by expression of wild-type PTEN (Haas-Kogan et al., 1998). 
Extensive genomic deletions involving chromosome 10 are the most common 
genetic alteration in GBM. In fine mapping of CRD in chromosome 10 of 198 
astrocytic tumors using 53 microsatellite markers, a locus close and distally 
located to the PTEN gene showed pattern of homozygous deletion in four GBMs 
(Ichimura et aL’ 1998). LOH around PTEN is closely associated with a reduced 
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overall survival (P 二 0.002) but LOH at other gene locus (DMBTl and NEURL) 
within 10q23.3 — q26.1 is not (P > 0.05; Fan et al., 2002). There might be other 
candidate genes on lOq, but PTEN is considered as a TSG, based on two-hit 
inactivation and confirmed by ftinctional analysis. 
Frequent loss and homozygous deletion in locus surrounding PTEN, and 
mutation at PTEN were detected in GBM but not in diffuse astrocytoma and AA 
(Fan et al., 2002; Smith et al.’ 2001; Steck et al., 1999). In concordance with the 
significantly lower frequency of PTEN mutation in both AA and diffuse 
astrocytoma than GBM, PTEN mutations were found in 12% {n = 17) of primary 
GBM but not in secondary GBM {n = 13; Fujisawa et al, 1999 and 2000). In 
secondary GBM, TSGs other then PTEN are likely to be involved because 
10q25 — qter (and 19ql3.2 — ql3.4) deletions without PTEN mutation were 
detected among 5 secondary GBMs. 
Patients with AA harboring PTEN alteration have statistically significantly 
worse survival than patients without PTEN alteration after adjustment for age, on-
study performance score and extent of tumor resection (Smith et al‘, 2001). 
Retinoblastoma (RB) 
RB plays a role in cell cycle control by encoding the nucleoprotein (pRb) that 
acts as the molecular switch in the restriction point of Gl/S transition. In late Gl, 
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pRb is phosphorylated by the cyclin D-Cdk 4/6 complexes, so as to release the 
nuclear proteins and transcription factors (E2F family) for entrance into the S 
phase. On the contrary, hypophosphorylated form of pRb induces G1 cell cycle 
arrest (Buchkovich et al., 1989). 
LOH at RB locus (13ql4.1 — ql4.2) occurs in 30% of high-grade tumors (2 of 
10 AAs and 14 of 44 GBMs), significantly higher than in diffuse astrocytoma 
(none of 12; P = 0.025). Except one case, no LOH could be detected in adjacent 
loci in cases without LOH at RB. However, only 2 inactivating mutations and 2 
possible inactivating mutations of RB among the 7^-deleted samples was reported 
(Henson et al., 1994). The Knudson's two-hit criterion for tumor suppressors is 
not fulfilled because of the lack of cases harboring both loss and activating 
mutation of the same gene. However, RB transfection of xenografts resulted in 
loss in neoplastic morphology and G1 phase arrest, supporting the role of RB in 
tumor growth suppression (Fueyo et al, 1998). 
LOH on 13q was detected in 12% (2/17) of primary and 38% (5/13) of 
secondary GBM and typically included the RB locus (Nakamura et al.’ 2000). No 
mutations were detected in promoter and exon regions of RB among 63 astrocytic 
tumors (32 primary GBMs, 10 secondary GBMs and 21 AAs). However, among 
the same 63 tumors, aberrant methylation was detected in 16% of the primary 
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GBMs, 40% of the secondary GBMs and 14% of the AAs (Gonzalez-Gomez et al., 
2003). Knudson's two-hit criterion is fulfilled by methylation and loss of allele. 
Promoter methylation of RB was not found in 15 diffuse astrocytomas and 10 
AAs. Promoter hypermethylation of RB in secondary GBM (43%, n = 21) is 
significantly more frequent than in primary GBM (14%, « = 35; P = 0.0258). 
(Nakamura et al‘, 2001a). Combining the LOH and methylation results, RB 
alterations occur lately during astrocytic tumor progression and its role is more 
significant in secondary GBM. 
pl6iNK4A from the INK4 family acts as the inhibitor of Cdk4/6. Theoretically, 
disruption of together with p i a n o t h e r member of the INK4 
family, would lead to a prominent growth advantage for a tumor cell (Simon et al., 
1999). p i 脳 A jg the principal target in the 9p21 loss region. Moreover, 
hypermethylation of promoter region involving multiple sites in a 5'-CpG island 
is associated with inactivation o f ( H e r m a n et al., 1996). 
The role of in astrocytic tumorigenesis was confirmed by its 
correlation with negative immunoreactivity (Park et al., 2000). Also, 
demethylation of pi by 5-aza-2-deoxycytidine treatment led to re-expression 
of pi 6腦A (Costello etal., 1996). 
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pi6删A infection of rat GBM cell line RT-2 resulted in 98% reduction in 
colony formation and 60% reduction in growth. Exogenous overexpression of 
induced hypophosphorylation of Rb. The cells were unable to enter S 
phase, probably due to the binding of 口161服4八 t � C d k 4 (Hung et al” 2000). 
By differential PGR, frequency of homozygous deletion of plG^^"^^ detected 
was higher in primary (32%, n = 34) than secondary (13%, n = 16) GBM. On the 
contrary, higher promoter hypermethylation was detected in secondary GBM 
(19%) than primary GBM (3%). Therefore, frequency alterations is 
similar in primary and secondary GBM (Nakamura et aL, 2001b). 
pl严 
shares the same genomic locus with 卩16^碰 although they are 
structurally unrelated. Binding of pl4从卩 ^ a complex of Mdm2 and p53 
prevents the Mdm2-mediated degradation of p53. Therefore, p i i s a potent 
tumor suppressor in the presence of wild-type p53 (Simon et al.’ 1999). 
Targeted deletions in the gene do not result in tumor formation. 
However, loss of results in dedifferentiation in response to appropriate 
oncogenic stimuli. Combined K-Ras and Akt signaling could induce GBM 
formation from neural progenitor cells but not differentiated astrocytes. 
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Deficiency of cooperated with K-Ras alone in tumor formation from both 
neural progenitor cells and astrocytes (Uhrbom et al., 2002). 
Deletion of p J 4 ^ is associated with co-deletion of 口]6服4几 and increase in 
frequency upon progression from low- to high-grade in astrocytic tumors. 
Interestingly, frequency of p l 4 ^ alterations is higher than that of pl6 狐 . 
Nakamura et al. (2001b) detected simultaneous homozygous deletion of pl^^ 
and pJ6腦A 13 GBMs，whereas 9 GBMs showed pi严 deletion alone. No 
single case showed deletion alone without deletion. Overall, 16 
GBMs showed both alterations in pi严 and pi6腦a, and 13 GBMs showed 
alterations alone. Except for one case with 口化工脳八 methylation alone, 
there was no GBM with 卩16狐4八 alteration without concurrent alteration. 
Similarly, Labuhn et al. (2001) reported higher homozygous deletion and 
promoter hypermethylation of the gene than pl6 
Although methylation occurs in both GBM subtypes, deletion 
and TP53 deletion are mutually exclusive，suggesting functional redundancy of 
the 2 genes in astrocytoma tumorigenesis (P < 0.01, n = 20; Fulci et al., 2000). 
Homozygous deletion and promoter hypermethylation of the gene occurs 
in 44% and 31% of 34 primary GBMs, respectively. They also account for 44% 
and 6% of 16 secondary GBMs, respectively. No overall statistical significant 
difference {P 二 0.129) exists between the two GBM subgroups. Among 15 
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secondary GBMs with homozygous deletion, 33% of the paired diffuse 
astrocytomas were hypermethylated in promoter of with no homozygous 
deletion detected (Labuhn et al” 2001). This suggests that homozygous deletion 
is a later event than hypermethylation. 
1.2.4. Oncogenes 
EGFR and mouse double minute 2 homolog (MDM2) are the current 
confirmed oncogenes identified in astrocytic tumors. 
Epidermal srowth factor receptor 
EGFR was the first amplified gene discovered in human GBM (Libermann et 
al., 1985). In search for amplification of tumor-related genes located on 
chromosome 7, EGFR was reported as the only gene amplified among 16 
astrocytic tumors (6 of 10 GBMs, 2 of 2 AAs，and 4 of 4 diffuse astrocytomas; 
Torp et al., 1991). Quantitative DNA dot blots revealed EGFR amplifications in 6 
of 14 GBMs (Hurtt et al., 1992). In another study, the EGFR locus (7pl2.3 — 
pl2.1) was the most commonly and highly amplified (Liu et al., 1998). 
EGFR encodes a receptor-tyrosine-kinase (RTK) with an extracellular ligand 
binding domain, a transmembrane domain and intracellular tyrosine kinase 
domain, and additional amino acid sequences that function as regulatory domains 
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(Lemmon and Schlessinger, 1994). Ligand binding induces receptor dimerization， 
autophosphorylation in a tram fashion and elevated tyrosine kinase activity of the 
RTK. The binding of epidermal growth factor (EGF) leads to simultaneous 
activation of multiple pathways, including the extensively studied 
Ras/Raf/Mek/Erk pathway (Jorissen et al., 2003). 
EGFR amplification was significantly less common in AA than GBM {P = 
0.001, n ^ 63 and 111; Smith et al., 2001), revealing its role at later stage of 
malignancy change. Both EGFR amplification and EGFR over expression are 
more frequent in primary GBM. EGFR amplification was found in about 50% 
(25/49) of primary GBMs but not in secondary ones (0/33; Fujisawa et al., 2000 
and Libermann et al., 1985). Virtually all tumors with EGFR amplification 
showed EGFR overexpression (Libermann et al, 1985). About 40% of primary 
GBM overexpressing EGFR harbor EGFR amplification (Harada et al., 2000). 
EGFR overexpression was detected in about 70% (15/22) of primary GBMs. 
Among 20 secondary GBMs, only 2 samples showed EGFR overexpression. 
Tumorigenicity of EGFR was demonstrated by overexpression of normal 
human EGFR in fibroblast culture (Haley et al., 1989). Anti-sense EGFR RNA 
transfection in human malignant gliomas cell U87MG led to increase of cell 
population in G1 but decrease in S phase, and reduced transforming potential as 
determined by soft agar assay (Tian et al., 1998). 
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More than half of GBMs with amplified EGFR genes also show co-
amplification of rearranged EGFR genes and express of aberrant mRNA species 
concomitantly (Ekstrand et al., 1991). The most common mutant EGFRvIII 
contains a deletion of exons 2 - 7 , encoding a constitutively autophosphorylated 
protein which could not be efficiently down-regulated (Fenstermaker and 
Ciesielski，2000). 
Interestingly, neither addition of EGF nor expression of EGFRvIII affects rate 
of cell growth in culture. However, tumorigenic capacity was greatly enhanced 
when cells expressing EGFRvIII were implanted specifically into brain of nude 
mice. Therefore, EGFRvIII promotes growth by influencing interactions of tumor 
cells in a way that cannot be assayed in vitro (Nishikawa et al., 1994). 
Simultaneous EGFR overexpression and TP53 mutation is rare. In Fujisawa et 
a/.，s study (2000), only one such case occurred out of 49 GBMs examined. 
However, Okada et al. (2003) accounted the exclusive pattern of TP53 mutation 
and EGFR amplification to the uses of GBM lysates. In their FISH study, EGFR 
amplification in GBM harboring TP53 mutation occurred in the cellular level at 
invading edges of tumor tissue. Therefore, frequency of EGFR amplification in 
secondary GBM might vary due to different sampling location of tumor. 
24 
Mouse double minute 2 homolos (MDM2) 
Mdm2 mediates p53 degradation via the ubiquitin-proteosome pathway and is 
itself a target of p53, completing a negative feedback loop (Chen et al., 1999; 
Leng et al., 2003). Mdm2 also acts as a bridge in formation of pRb-Mdm2-p53 
trimeric complex, enabling the modulation of ap opto sis by pRb (Yap et al., 1999). 
In mapping of amplicons within the 12ql3 - ql4 in 234 CNS tumors, MDM2 
at 12ql4.3 - ql5 showed preferential involvement with other two genes (CDK4 
and SAS). Although MDM2 was not the most frequently included gene in the 
amplicon of 12q, it was detected at the highest levels of amplification when co-
amplified. Amplification of MDM2 without the other amplicons was also 
reported (Reifenberger et al., 1994). Therefore, MDM2 is very likely an oncogene 
on 12q. 
Oncogenicity of MDM2 was later reflected by invasive activity of neonatal rat 
astrocytes overexpressing Mdm2 (Kondos et al., 1996). TP53 mutation and LOH 
on chromosome 17, with one exception were not detected among the astrocytic 
tumors showing MDM2 amplification (Reifenberg et al., 1993; Schiebe M et al.， 
2000). Mdm2 immunoreactivity was also associated with low or negative p53 
expression (Biernat et al‘, 1997; Dietzmann et al., 1996). This reflects the 
complementary role of TP53 and MDM2 alterations in tumorigenesis. 
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MDM2 amplification was detected in similar frequency in AA and GBM 
(Reifenberger et al., 1994). Amplification of the gene was detected in 2 of 29 
primary GBMs but not in 27 secondary GBMs examined. Immunoreactivity for 
Mdm2 was found in 52% {n = 29) primary GBMs but only 11% {n 二 27) 
secondary GBMs (P = 0.0015; Biernat et al., 1997). Hence, alterations in MDM2 
are present in both AA and secondary GBM, but are more prominent in primary 
GBM. Survival estimation revealed a significant correlation of MDM2 gene 
amplification or over expression with shorter survival time (Burton et al., 2002; 
Schiebe etal., 2000). 
On the other hand, a significantly higher frequency of short alternative splice 
transcripts ofMDM2 in GBM than AA and diffuse astrocytomas (22 of 32 GBMs, 
5 of 17 AAs, and none of 12 diffuse astrocytomas; P < 0.0003) was detected using 
a nested reverse transcription-PCR technique (Matsumoto et al., 1998). The 
presence of Mdm2 splice variants do not have apparent correlation with p53 status, 
suggesting a different mechanism of tumorigenesis caused by shortened 
transcripts, which may or may not be related to pRb-Mdm2-p53. 
1.2.5. Primary and secondary GBMs 
Genetic and epigenetic alterations in primary and secondary GBMs were 
summarized in Figure 1.1. Despite most genetic abnormalities are present in both 
26 
tumor subtypes, they differ greatly in frequencies, favoring the division of primary 
and secondary GBMs into 2 subgroups. Primary GBM is characterized by EGFR 
and MDM2 amplification/overexpression, PTEN mutations, LOH on entire 
chromosome 10, while secondary GBM shows frequent TP53 mutations and LOH 





















































































































































































































































































































































Fig 1.2. Genetic and epigenetic alterations in primary and secondary GBMs. 
� — 中 Differentiated Astrocytes or precursors 
TP 53 mutation (85%) 
EGFR amplification (50%) 
p l4娜 methylation (6%) 
MDM2 amplification (7%) | � •：> 
Chromosome 19q LOH (54%) 
PTEN mutation (12%) ,, 
rrL>.-T"' - .-... • ‘ 一. 了 - - • —_• • . —. .... 
Chromosome 10 LOH 了 
(lOp 47%; 10q41%) 
Chromosome lOq LOH (54%) 
p 14 娜 homozygous deletion (44%) / p 14 娜 homozygous deletion (44%) / 
methylation (31 %) methylation (6%) 
homozygous deletion (32%) / p i 6腳 a homozygous deletion (13%) / 
methylation (3 %) methylation (19%) 
RB methylation (14%) RB methylation (43%) 
i _ •, 
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Although alterations in chromosome 10 are involved in both primary and 
secondary GBM, their patterns of abnormalities are different. Among studies on 
sub-classification of GBM, LOH analysis on chromosome 10 using 28 
informative markers revealed LOH in all markers in the majority (88%, n = 17) of 
primary GBM. In contrast, only partial or complete loss of lOq, with retention of 
lOp was detected in secondary GBM (Fujisawa et al., 2000). 
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i.5. Major pathways involved in astrocytic tumorigenesis 
Not only could the genetic and epigenetic alterations help in sub-classification 
of astrocytic tumors into different subtypes, they could also help in explaining the 
genetic pathogenesis of the tumors. Most of the alterations, if not all, could be 
incorporated into two major pathways, the cell cycle pathways and the growth 
factor-regulated signaling pathways. The p 1 c e l l cycle pathway 
and pl4^^/Mdm2/p53 cell cycle arrest pathway play a prominent role in glial 
transformation. Dysregulation of polypeptide growth factors acting via RTKs, 
and of intracellular signaling through RTKs plays a critical role in tumor 
progression. 
1.3.1. Cell cycle dysregulation and suppression of apoptosis 
The cell cycle clock is regulated by cyclins which assemble with their catalytic 
partners, the Cdks (Figure 1.3; Lundberg and Weinberg, 1999; Stevens and Fields, 
2002). On one hand, the cyclin-Cdk complexes are regulated by cyclin-Cdk-
activating kinases and serine/threonine phosphatase. On the other hand, they are 
negatively regulated by two families of Cdk inhibitors (CKIs), the INK4 family 












































































































































































The levels of cyclins vary periodically in tightly regulation of the cell cycle 
phase, with the D-type cyclins being the first group to be induced in response to 
mitogenic stimuli. In particular, progression to S phase requires the 
phosphorylation and hence, inactivation of pRb by cyclinE-Cdk2, allowing the 
release of E2F family of transcription factors for expression of S phase gene as 
well as the cyclin E. In the presence of mitogenic stimulation, the cells run 
through a restriction point and complete the cycle. Disruption of any component 
of the pl6iNK4A/cdk4/pRb pathway is sufficient to dysregulate the cell cycle. 
Analysis of 120 GBMs showed only 7 of the cases without apparent 
abnormality of>7(5腦乂，CDK4 or RB. Among 195 astrocytic tumors, only 2 of 
them had alterations in more than one of the three genes (Ichimura et al., 1996). 
Therefore, dysregulation of the cell cycle is a major event in pathogenesis of 
GBM and alteration in one of the components is enough to disrupt the running of 
the cell cycle clock. 
p53 plays a role in cell cycle control through the induction of 
expression. Cell cycle analyses showed glioma cells arrested in the G2 phase 
before undergoing cell death. Transfer of induced a G2 block but did not 
induce apoptosis. Co-expression of and p53 prevented gliomas cells 
from undergoing apoptosis (Gomez-Manzano et al., 1997). 
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The mechanisms by which p53 mediates apoptosis are unclear. p53-inducible 
genes may contribute to the induction of both death-receptor and mitochondrial 
apoptotic pathways (Vousden and Lu，2002). p53 may also mediate apoptosis by 
transcriptional induction of redox-related genes. The formation of reactive 
oxygen species then leads to oxidative degradation of mitochondrial components, 
culminating in cell death (Polyak et al., 1997). The requirement for activation of 
parallel apoptotic pathways is postulated (Pietenpol and Stewart, 2002). 
1.3.2. Promotion of proliferation and survival 
Cellular growth and survival are regulated by two parallel signaling pathways, 
the mitogen-activated protein kinase (MAPK) cascades and the Akt pathway. 
The MAPK cascade 
The basic signaling module of the MAPK cascade includes a G-protein 
working upstream of a core module consisting of three kinases: a MAPK kinase 
kinase (MAPKKK) that phosphorylates and activates a MAPK kinase (MAPKK), 
which in turn activates MAPK (Kolch, 2000). To date, six MAPK pathways had 
been identified. Among them, the Raf/Mek/Erk signaling cascade was the first to 
be characterized and has been intimately connected with the regulation of cell 
growth and differentiation. In this cascade, Ras is the G-protein, Raf is the 
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MAPKKK, Mek (MAPK/Erk kinase) is the MAPKK and Erk (extracellular-
signal-regulated kinase) is the MAPK (Hilger, 2002). 
In vertebrates, regulation of Raf/Mek/Erk is complex because the Ras family 
consists of four members (H-Ras, K-Ras4a, K-Ras4b, and N-Ras) whereas the Raf 
family comprises of C-Raf (Raf-1), A-Raf and B-Raf (Hagemann and Rapp, 1999). 
Mek and Erk are of 2 isoforms, Mek 1 and Mek 2, and Erkl and Erk2. 
Furthermore, B-Raf encodes at least 10 different protein isoforms resulting from 
complex alternative splicing (Barnier et al., 1995; Eychene et al., 1995). 
Alterations in the MAPK cascade in astrocytic tumors 
As EGFR amplification occurred predominantly in GBM but not in AA and 
diffuse astrocytoma, overexpression of wild-type or mutant EGFR is widely 
thought to contribute to the malignant phenotype of GBM. However, the 
mechanism of how EGFR contribute to proliferation and survival is not well 
understood. The Ras protein, which complex with RTK through Growth factor 
Receptor-Bound protein 2 (Grb2) and Son of sevenless, drosophila homolog 1 
(Sosl), has been considered as the downstream effector which relays signals to the 
MAPK cascade. 
RAS mutation was detected in 30% of all human cancers (Bos, 1989). SSCP 
screening of codons 12 and 61 of the H�K-, and N-RAS oncogenes in biopsies 
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from 18 GBM patients did not yield aberrant band or mutation (Gomori et al” 
1999). Nevertheless, blocking Ras activation by expression of the H-RAS-Asnl7 
dominant negative mutant or by farnesyl transferase inhibitors decreased in vitro 
proliferation of human astrocytomas cell lines (Guha et al., 1997). 
Overexpression of H-RAS for transformation of astrocytes activated Ras in vivo 
(Ding et al., 2001). Transgenic mouse astrocytoma mirrored both the 
histopathology and molecular profile of human malignant astrocytomas. 
Experiments with EGFR kinase inhibitor PD158780 showed the contribution of 
spontaneously activated EGFR to constitutive phosphorylation of Erk but not 
members of the Akt pathway in the astrocytic tumor cell line SKMG3 (Thomas et 
al, 2003). 
According to Mandell et al. (1998), Erk is highly activated in both low-grade 
and malignant gliomas. Erk phosphorylates and activates several targets in 
growth control. Activation of the transcription factor Elk-1 leads to the 
expression of immediate early genes, including v-myc avian myelocytomatosis 
viral oncogene homolog (MYC) which may regulate cell cycle at multiple points. 
Increased MYC protein expression may promote Gl/S transition by attenuating 
the expression of the Cdk inhibitor The activation of results in 
hi stone H3 phosphorylation, increasing accessibility of transcription factor to 
36 
RS K. 
DNA. p90 activation also inactivates Mytl, a kinase that phosphorylates and 
inactivates the Cdkl/Cdc2 kinase for G2/M transcription. Activation of 
carbamoyl phosphate synthetase allows pyrimidine-nucleotide synthesis. Lastly, 
activation of MAPK-interacting kinase 1 (Mnkl) would in turn activate the 
eukaryotic translation initiation factor eIF-4E for synthesis of rapid-response 
genes for growth (Besson and Yong, 2001; Shapiro, 2002). Erk also promotes cell 
survival and may contribute to tumorigenesis by phosphorylation and inhibition of 
caspase-9 (Allan et al., 2003). 
The Akt pathway and PTEN in astrocytic tumors 
Upon activation of membrane receptors by growth factors and survival factors 
PI3K is recruited to plasma membrane. This results in phosphorylation of 
membrane lipids PtdIns-4-P and PtdIns-4,5-P2, and production of the second 
messengers ptdIns-3,4-P2 and PtdIns-3,4,5-P3. The second messengers in turn 
recruit Akt and Phosphoinositide-dependent protein kinase 1 (Pdpkl) to the 
membrane and expose the activation loop in Akt. Phosphorylation of Akt at T308 
of the activation loop by Pdpkl turns on the protein kinase activity. 
Phosphorylation of Akt at C-terminal site causes further activation (Cantley and 
Neel, 1999). 
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Akt down-regulates levels and inhibits glycogen synthase kinase 3, 
which phosphorylates and targets cyclin D for proteolysis (Cantley and Neel, 1999; 
Di Cristofano and Pandolfi, 2000). It also phosphorylates and retains 
and p27幻PI in the cytoplasm. Not only promoting cell cycle progression, 
cytoplasmic also binds to the Apoptosis-signal-regulating kinase (Askl) 
to inhibit apoptosis. Furthermore, Akt phosphorylates and compromises the 
function of BCL2-antagonist of cell death (Bad) and caspase-9, proteins involved 
in apoptosis (Liang and Slingerland，2003; Testa and Bellacosa，2001). 
Under serum-free conditions, human GBM cell lines with Akt activation 
exhibited only weak phosphorylation of MAPK signal pathway, whereas those 
cell lines lacking constitutive Akt activation demonstrated high levels of 
phosphorylation (Schlegel et al., 2000). However, in AA and GBM, PTEN 
mutation was known to co-operate with EGFR activation to increase vascular 
endothelial growth factor (VEGF) mRNA levels by transcriptionally up-regulating 
the proximal VEGF promotor via the Akt pathway (Pore et al.) 2003). 
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1,4. B-Raf mutation in human cancers 
Raf was linked to Ras in 1992 and 1993 (Avruch et al., 1994). However，Raf 
was related to cancer independent of Ras only recently，through the Cancer 
Genome Project (CGP) by Davies et al. (2002). CGP is a systematic genome-
wide screen for mutations in genes that are related to the regulation of cell 
proliferation, differentiation and death. The authors postulated the involvement of 
at least one gene mutation in the signaling pathways and succeeded in discovery 
of BRAF mutations in a variety of human cancers. 
In general, the family of Raf proteins is invol ved in regulation of proliferation, 
differentiation, and apoptosis. They are overlapping in function but are tissue 
specific and might differ in the regulation of their activation and their ability to 
connect to downstream signaling pathways (Hagemann and Rapp, 1999). All Raf 
proteins are cytosolic. C-Raf transcript is expressed ubiquitously in the mouse, 
with highest expression levels in striated muscle, cerebellum, and fetal brain. A-
Raf is preferentially expressed in urogenital tissue. B-Raf shows highest 
expression levels in neuronal tissues and testis (Naumann et al.’ 1996). Of the 
three kinases, A-Raf has the lowest binding affinity towards Ras. Therefore, an 
alternative activator for A-Raf may exist (Weber et al., 2000). In vitro, B-Raf has 
a higher binding affinity for Mek and displays a higher Mek kinase activity than 
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C-Raf (Papin et al., 1998). Furthermore, maximal B-Raf activity requires only 
oncogenic Ras, while A-Raf and C-Raf require synergized activation of Ras and 
Src (Marais et al, 1997; Mason etal., 1999). 
In screening of the coding exons and intron-exon junctions of the BRAF gene 
in 15 cancer cell lines consisting of six breast cancers, one small cell lung cancer, 
six non-small cell lung cancers, one mesothelioma and one melanoma for 
sequence variants, three single-base substitutions were detected. Two were in 
exon 15: T1796A leading to a substitution of valine by glutamic acid at position 
599 (V599E) and C1786G leading to L596V. The one in exon 11 was G1403C 
leading to G468A. All were somatic mutations because none of the three changes 
were detected in lymphoblastoid cell lines from the same individuals. 
Further screening of 530 cell lines also revealed BRAF mutations in exons 11 and 
15. Accordingly, the two exons were screened for mutations in genomic DNA 
from 378 primary human cancers and short-term cultures. BRAF mutations were 
detected in 67% of primary melanoma, 12% of primary colorectal cancer, 14% of 
primary ovarian cancer and many other tumor types. Base substitution was also 
detected in four (DBTRG-05MG, KG-l-C, AM-38 and NMC-Gl) of 38 glioma 
cell lines (Davies et al., 2002). 
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The three Raf proteins are conserved in three conservative regions (CRs; 
Mercer and Pritchard, 2003; Figure 1.4). CRl consists of the Ras binding domain 
(RED) and a cysteine-rich domain. CR2 is rich in serine and threonine residues 
and is thought to be involved in phosphorylation regulation of the Raf proteins. 
The BRAF mutations in various human cancers lie in the third CR. All of the 
mutated amino acid residues (G463, G465 and G468) in exon 11 lie in the G-loop 
of ATP binding region and all (F594, G595, L596 and V599) except E585 in exon 
15 lie in the activation segment of B-Raf. Out of the mutants, 80% were V599E 
base substitution (Davies et al., 2002). 
After the discovery of BRAF as an oncogene, studies on BRAF in dysplastic 
tissues, expanded cancer series and cell lines were performed by different groups. 
BRAF mutations were detected in 46% of papillary thyroid cancer, 21.7% of 
cholangiocarcinoma, 33.3% of hyperplastic polyp (Table 1.3 and 1.4). Other than 
the mutation sites just mentioned, large number of other base changes were also 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1.4. Frequencies of BRAF mutation in human cell lines. 
Data complied from Cohen et al. (2003) and Davies et al. (2002). 
Cell line No. of Mutations No. of cases % 
Thyroid cancer 6 9 66.7 
Melanoma 20 34 58.8 
Colorectal cancer 7 40 17.5 
Glioma 4 38 10.5 
Sarcoma 5 59 8.5 
Ovarian cancer 1 26 3.8 
Lung cancer 4 131 3.1 
Breast cancer 1 45 2.2 
Bladder cancer 0 10 0 
Neuroblastoma 0 29 0 
Cervical cancer 0 11 0 
Gastric carcinoma 0 6 0 
Leukaemia & Lymphoma 0 53 0 
Pancreatic carcinoma 0 3 0 
Prostate cancer 0 3 0 
Renal cell caicinoma 0 11 0 
Testicular carcinoma 0 7 0 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The functional regulation and activation of B-Raf is partly implied by 
sequence comparison with C-Raf. The inactive C-Raf is phosphorylated in S259 
and S621 that bind 14-3-3 proteins retaining C-Raf in an inactive, closed 
conformation. Upon stimulation, 14-3-3 is displaced from C-Raf by Ras-GTP. C-
Raf is then translocated to the plasma membrane, where it is dephosphorylated at 
S259 by phosphatase such as PP2A (Abraham et al., 2000; Dhillon et al.) 2002). 
Similarly but with a more open conformation, B-Raf is rendered inactive by 
phosphorylation of S364 and S728 (MacNicol et al.，2000). The phosphorylation 
of S259 of C-Raf and S364 of B-Raf (at equivalent positions) appears to be 
negatively regulated by Akt (Guan et al., 2000; Zimmermann and Moelling, 1999). 
One crucial event in Ras-induced activation of C-Raf is phosphorylation of 
S338. The corresponding amino acid residue in B-Raf is the constitutively 
phosphorylated S445. Phosphorylation of T341 by Src family is also essential for 
C-Raf activation. In B-Raf, the equivalent position to Y340 and Y341 are D447 
and D448. B-Raf activation without tyrosine kinase signals is attributed to the 
negative charges of the aspartic acid, which may mimic phosphorylated residue 
(Marais et al., 1997; Mason et cd., 1999). T598 and S601 located within the 
activation segment were identified as additional major phosphorylation sites of B-
Raf at the membrane in response to oncogenic Ras (Mercer and Pritchard, 2003). 
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Biological effects of BRAF mutations were characterized by expression of 
cDNA containing V599E, L596V，G463V and G468A mutations in cell lines. 
Kinase-activated B-Raf mutants were able to induce transformation because 
cDNA constructs in NIH3T3 cells increased focus-forming ability of the cells. 
Not only did the mutants possessed elevated basal kinase activity (V599E, 10.7-
fold; L596V, 5.7-fold; G463, 2-fold; G468A, 12.5-fold) in COS cells, they were 
also capable to stimulate endogenous Erk (Davies et al., 2002). 
The V599E is distinct from other B-Raf mutations because none of the 51 
tumors series in Davies et a/. 's study which harbor V599E mutation contained K-
RAS or N-RAS mutation. Whenever, simultaneous mutation of BRAF and RAS 
mutation were detected, it was non-V599E. Proliferation requirement of V599E 
mutant cells is uncoupled from Ras activation, although in vitro data indicated 
further activation by mutant Ras. The cell lines with V599D, G465V, G463V and 
L596V mutation remained dependent on Ras function (Davies et al., 2002). 
Micro satellite instability (MSI) in sporadic colorectal cancer often results from 
epigenetic inactivation of the DNA mismatch-repair gene, MLHl in association 
with DNA methylation (Herman et al.，1998). In studies of BRAF mutation 
pattern in colorectal neoplasia, significantly higher frequency of BRAF mutation 
was found in mis match-rep air-deficient tumors than in mismatch-repair-proficient 
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ones (Rajagopalan et al., 2002; Wang et al., 2003). The correlation of BRAF 
mutation with mismatch-repair deficiency suggests vulnerable structural or 
sequence elements surrounding BRAF codon 599 in repair-deficient background. 
In Wang et a/.，s study (2003), about 60 of 293 colorectal cancers harbored V599E 
mutation. Within 31 samples with both MLHl alterations and BRAF mutation 
among 293 colorectal cancers, 30 were hypermethylated in their promotors and 
the remaining one harbored MLHl germline mutation. Therefore, epigenetics 
account for at least half (31/60) of BRAF mutations in colorectal cancer. 
The timing of mutations in melanoma tumorigenesis was investigated by 
screening of BRAF mutations in nevi. Mutation of V599E in nevi (82%) is as 
high as in primary melanoma (80%; Pollock et al., 2003), suggesting a role of 
BRAF mutations in melanoma initiation. Regarding nevi as premalignant 
precursors of melanoma, the mutational activation of the Ras/Raf/Mek/Erk 
pathway would be critical in tumorigenesis but alone is insufficient for 
tumorigensis. Moreover, BRAF mutations were detected in only 10% of the 
earliest stage of rapid-growth-phase melanomas in contrast to a 75% of melanoma 
in vertical-growth-phase (Dong et al., 2003). Based on the increase in BRAF 
mutation frequency with tumor grade, the author suggested a role of BRAF 
mutation in tumor progression rather than initiation. Whether BRAF mutation 
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provides an advantage in tumor initiation and/or proliferation requires further 
studies. 
The dysregulation of growth regulatory pathways in melanoma could be 
summarized into four levels: 1) aberrant production of autocrine growth factors 
that substitute for exogenous growth factors; 2) alterations in response to negative 
autocrine growth factors; 3) overexpression of EGFR; and 4) alterations of 
cellular protooncogenes involved in signal transduction and growth suppression 
(Rodeck, 1993). Although the sequential alterations in melanoma could not be 
applied directly to the astrocytic tumors, the autocrine activation of melanoma 
cells could provide hints on tumorigenesis of astrocytic tumors, in which EGFR 
overexpression occurs frequently� 
Using melanoma cell lines with activating mutations in the kinase domain of 
BRAF, neutralization on fibroblast growth factor (FGF) and hepatocyte growth 
factor (HGF) dramatically inhibited Erk activation. Thus, constitutively activated 
Erk is apparently mediated by excessive growth factors through autocrine 
mechanisms and B-Raf kinase activation in melanoma (Satyamoorthy et al., 2003). 
Likewise, BRAF mutations in other cancers, including astrocytic tumors, may also 
be related to alterations in members of mitogenic signaling pathway. 
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1.5. Other CNS tumors included in the current study 
Classifications of CNS tumors have been based on theories of histogenesis, 
grades of dedifferentiation/anaplasia, or a combination of these. However, 
heterogeneous variants within a tumor type await sub-classification or even 
reclassification by genetics. Brief information on the GBM variant gliosarcoma 
and other CNS tumors included in this study are provided as follows: 
Gliosarcoma 
Gliosarcoma (GS; WHO IV) is a GBM variant characterized by a biphasic 
tissue pattern with alternating areas displaying glial and mesenchymal 
differentiation (Kleihues and Cavenee, 2000). It constitutes 2 — 8% of all GBM 
(Meis et al., 1991; Morantz et al., 1976) and does not differ from the majority of 
GBM with regard to age, sex, pretreatment Karnofsky performance status, tumor 
location, size, median survival, and actuarial survival (Meis et al., 1991). 
Nevertheless, GS is more likely to metastasize (Morantz et al.，1976). In 
Lutterbach et al.'s study (2001), all of eight GS patients treated at their hospital 
between 1980 and 1999 had local tumor recurrences. 
GS shows genetic aberrations similar to those occurring in primary GBM. 
None of 19 GSs showed amplification or overexpression of EGFR (Reis et al.， 
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2000). However, the number of chromosomes involved in imbalances in GS was 
significantly lower than that in GBM, indicating a higher genomic stability. 
CGH study revealed that the gliomatous and sarcomatous components shared 
57% of the chromosomal imbalances (Actor et al., 2002). Genetic studies 
supported a monoclonal origin of the two components that progressed into sub-
clones. Gain or amplification of genes on proximal 12q may facilitate the 
development of the sarcomatous phenotype (Actor et a/., 2002; Reis et al., 2000). 
Olisodendroslial tumors and mixed tumors 
Oligodendroglial tumors constitute about 5% of all primary gliomas. They 
occur most commonly in the cerebral hemispheres of adults in a mean age of 
about 40 years. Male/female ratio ranged from 1.1:1 to 2:1. Oligodendroglioma 
is diffusely infiltrating tumor composed predominant of cells morphologically 
resembling oligodendrocytes. Depending on the presence or absence of focal or 
diffuse histological features of malignancy, the tumor is classified into WHO 
grade II or III (Kleihues and Cavenee, 2000). 
The two most frequent genetic alterations in oligodendroglial tumors, is LOH 
on chromosomes 19q and Ip，both linked significantly to better response to 
chemotherapy independent of tumor grade (Goussia et al., 2001; Reifenberger and 
53 
Louis, 2003). Deletion regions were identified at lp34 - p35, lp36.3 and 19ql3.3 
(Husemann etal., 1999; Rosenberg etal., 1996; Yong et al., 1995). 
Promotor hypermethylations were detected in multiple genes, including O^-
methylguanine-DNA methyltransferase (MGMT), RB，estrogen receptor, TP73， 
pi6臓A, death-associated protein kinase, p l f ^ , pj[严 at 60%, 34%, 30%, 
16%, 12%, 10%, 7%, and 2%, respectively. Concordant hypermethylation of 
and pi^iNiom were significantly associated with anaplastic 
oligodendroglial tumors. Hypermethylation of MGMT in chromosome 10q26 
was significantly associated with LOH at 19q and combined LOH of lp/19q 
(Dong et al.) 2001). Mutation was undetected in TP73, but expression of the gene 
was transcriptionally inactivated by hypermethylation. Therefore, TP73 may have 
an epigenetic origin (Dong et al., 2002a). 
Indicators of poor response to therapy and short survival included 
homozygous deletion of pi^iN碰,mutation of PTEN and amplification of EGFR 
(Reifenberger and Louis, 2003). In contrast to astrocytic tumors, loss of 17p and 
mutations in TP53 were rare (Smith et al‘, 2000; Ueki et al., 2002). 
Oligoastrocytomas (WHO II & III) are mixed glial tumors that show 
morphologic features of oligodendroglioma and diffuse astrocytotma. According 
to Dong et al. (2002b), origin of oligoastrocytomas can be monoclonal or derived 
from different precursor. The first subset is characterized by allelic loss on Ip and 
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19q, and advanced variants with loss also on 9p, lOq, 13q and/or 17p. The second 
subset showed divergent allelic loss patterns in the two histologic component with 
mutation and overexpression of TP53 detectable in the astrocytic components only. 
In the same year, temporal oligoastrocytomas was found to be different from 
frontal, parietal and occipital tumors due to their relative low frequency of LOH at 
Ip and 19q (Mueller et al, 2002). 
Eyendymal tumors 
Ependymal tumors arise from the ependymal lining of the cerebral ventricles 
and the remnants of the central canal of the spinal cord. Age distribution of 
patients ranges from less than 1 year to more than 80 years. However, the disease 
occurs predominantly in children and adolescents. In children, ependymomas are 
the third most frequent brain tumors and account for 6 - 12% of all paediatric 
CNS tumors (Lamszus et al., 2001; Goussia et al., 2001). In children, 90% of 
tumors are intracranial and 10% are intraspinal. In adults, 60% are tumors of 
spinal cord and only 40% are intracranial (Vagner-Capodano et al.’ 1999). While 
ependymoma (WHO grade II) often causes clinical symptoms by blocking CSF 
pathways, subependymoma (WHO grade I) is often detected incidentally and has 
a very favorable prognosis (Ebert et al., 1999; Prayson and Suh, 1999). 
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Cytogenetic and molecular genetic studies have revealed numerous 
chromosomal abnormalities in ependymomas, with monosomy 22 or structural 
rearrangements of chromosome 22 being the most frequent abnormality (Vagner-
Capodano et al., 1999). By CGH, our group member found loss on chromosomes 
22q, 16, 17, 6, 19, 20 and Ip, and detected chromosome gain in 5q, 12q, 7q, 9q 
and 4q (Zheng et al., 2000). Frequent (at least 50%, 16 ependymomas) was later 
detected in 6q, 13q，16p, 16q, 17q, 19q, 20p, 20q and 22q by allelotyping using 
384 polymorphic markers. CRD on chromosome 22 was mapped to 22ql3.1 — 
ql3.3. Allelic deletion was also detected on 22qll .2 in 25% cases ( long et al., 
2001). LOH in both regions were reproducible in a later study (Huang et al., 
2002). 
The neurofibromatosis 2 (NF2) gene located on chromosome 22ql2 was 
preferentially mutated in spinal ependymomas (Alonso et al‘, 2002; Ebert et al., 
1999; Rubio et al‘, 1994; Slave et al., 1995). Loss and mutation of NF2 fulfilled 
Knudson's two-hit hypothesis in the same tumors (Ebert et al., 1999; Lamszus et 
al., 2001). The region 22ql3.1 — ql3.3 may harbor TSGs other than NF2 in 
ependymomas. 
Another abnormality in ependymoma is LOH in chromosome 6q. Mutation of 
PTEN and TP53 gene, mutation or deletion of allelic loss on 
chromosome lOq and amplification of MDM2 and EGFR are very rare findings 
56 
and do not play a major part in the pathogenesis of ependymal tumors (Alonso et 
al., 2002; long et al, 1999). 
Medulloblastoma 
Medulloblastoma (MB; WHO IV) is the commonest malignant CNS tumor in 
children, accounting for 20% of childhood brain tumors. Classical MB occurs 
predominantly in midline cerebellum of children and is characterized by frequent 
dissemination of CSF at presentation. It is strongly associated with amplification 
of MYC, the possession of which is totally resistant to therapy and has a fatal 
outcome. In contrast, MB of desmoplastic histology are more frequently in lateral 
location. They occurred in an almost equal distribution between children (56%) 
and adults (44%), and have a better outcome (Mazzola and Pollack, 2003; 
Pramanik et al., 2003; Sarkar et al., 2002). 
Mutations in two genes were found to be significant for tumorigenesis of MB. 
Among 67 MBs, mutation of p-catenin from 3 cases was reported (Zurawel et al.， 
1998). In a later study, four activating mutations of P-catenin and two mutations 
of the adenomatous polyposis of the colon (AFC) gene were detected in 46 
sporadic MBs (Huang et al., 2000). APC forms a complex with two other 
proteins to down-regulate P-catenin, which translocates to the nucleus to activate 
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the transcription of various genes, including MYC. Therefore, the APC/|3-catenin 
pathway is responsible for tumorigenesis of certain MB subtypes. 
Approximately 3% of individuals with the Gorlin's syndrome were 
predisposed to MB (Evans et al’, 1991; Lacombe et al., 1990). The autosomal 
chromosomal abnormality leading to the familial syndrome was mapped to 9q22.3 
and was identified as PTCH (Hahn et al, 1996; Johnson et al., 1996). Afterwards, 
LOH in flanking region of PTCH was defined in sporadic MBs in various studies 
(Albrecht et al., 1994; Raffel et al., 1997; Schofield et al�1995). Then mutation 
of the PTCH gene was detected in desmoplastic MBs and fulfilled the two-hit 
criterion for tumor suppressors (Pietsch et cd.’ 1997; Raffel et al., 1997). 
The protein encoded by PTCH, patched act as the membrane receptor for 
sonic hedgehog signals together with smoothened proteins (Marigo et al., 1996; 
Stone et al., 1996). Binding of hedgehog proteins to patched receptor leads to de-
repression of smoothened and activation of glioma-associated oncogene homolog 
(Gli) transcription factors for downstream targets. 
Recently, somatic mutation in the suppressor of fused (SUFU) in chromosome 
lOq and LOH of the wild-type allele were detected in a subset of children carrying 
MB. SUFU acts as a negative regulator of the Hedgehog signaling pathway 
through two distinct mechanisms, either sequestration of Gli in the cytoplasm or 
interaction with Gli directly on DNA (Kogerman et al, 1999). Several of the 
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SUFU mutations encode truncated proteins that are unable to export Gli 
transcription factors form nucleus to cytoplasm (Ellison, 2002; Taylor et al” 2002). 
One of our group members performed CGH in 12 MBs and compared findings 
with previous genome-wide studies covering a further of 107 tumors. 
Summarized results revealed the most frequent deletions on 17p, lOq, 8p, l ip , 
l l q and 16q (Yin et al., 2002). Despite 17p loss occurs in 30 - 50% of MB, 
mutations in TP53 occur in less than 10% of sporadic MB. Therefore, other TSGs 
are probably involved in chromosome 17p (Ellison, 2002). By deletion mapping, 
a novel region of homozygous deletion was identified on 8p22 — p23.1 (Yin et aL, 
2002). 
Metiinsiomas and haemansiopericvtomas 
Meningiomas (mostly WHO I), in general, are slow-growing benign tumors 
attached to the dura mater and composed of neoplastic meningothelial cells. They 
comprise 20% of intracranial neoplasms, manifest typically in adults and show 
predominance for women, with a female/male ratio of 3:2 or even 2:1 
(Chamberlain, 2001; Heinrich et al, 2003; Kleihues and Cavenee, 2000). 
Haemangiopericytoma of the CNS, almost always attached to the dura, is highly 
cellular and richly vascularized. 
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Mutations in the NF2 gene are detected in up to 60% of sporadic meningiomas 
but not in haemangiopericytoma (Joseph et a/., 1995). Similar to ependymomas, 
Knudson's two-hit hypothesis was fulfilled in meningiomas (27%, n 二 26) by 
LOH of 22q markers and inactivating mutations in NF2. However, the majority 
of tumors carry allelic loss of 22q but intact NF2. This suggests the presence of 
other tumor suppressors in the long arm of chromosome 22. 
Distinction of haemangiopericytoma from meningioma was genetically 
supported by homozygous deletions of the 服“义 in about 25% of meningeal 
haemangiopericytoma but less than 5% in meningioma (Ono et al., 1996; 
Verheijen et al., 2002; Weber et al. 1997). 
Other than abnormalities of chromosome 22q, chromosome 14q loss was also 
common among meningiomas. LOH for one or more markers was detected in 
37% {n = 41) of meningioma, including 3 of 3 recurrent ones. CRDs were defined 
in 14q24.3 - q31 and 14q32.1 一 q32.2 (Tse et al., 1997), which overlaps with the 
region in astrocytic tumor (14q21.2 — q32.12 and 14q32.1 — qter; Hu et al, 2002). 
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2. Aims of study 
Owing to the infiltrating feature of astrocytic tumors, resection boundary is not 
distinct. Patients who receive tumor resection often have recurrences. While 
chemo- and radio-therapy could extend survival in some patients, they cause side-
effects and lower the quality of life. 
Patients with diffuse astrocytoma can survive for as long as ten years but carry 
latency for high-grade tumor. GBM patients diagnosed after two years are already 
described as long-term survivors. Therefore, more accurate criteria for diagnosis, 
prognosis and decision on treatment program require molecular sub-classification 
of the tumors. Hopes of cure rely on molecular understanding of the disease. 
Recently, Davies et al (2002) raised the role of BRAF as an oncogene 
independent of oncogenic RAS. BRAF mutations were detected in a large variety 
of primary human cancers including melanoma, colorectal cancer, ovarian cancer 
and non-small cell lung carcinomas (Brose et al., 2002; Davies et al.，2002). The 
BRAF mutation rate in melanoma ranges from 60 to 90%. 
In Davies et al:s study (2002), the base substitution leading to substitution of 
valine by glutamic acid at position 599 (V599E) in BRAF was found in 4 of 38 
glioma cell lines. However, no mutation was detected among 15 primary glioma 
specimens. This could be due to recruitment of inadequate samples. Gliomas 
include a wide range of neoplasms but diagnosis of primary glioma was 
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unspecified in their study. Involvement of different types of primary glioma 
within a small size could further lower the sample size of tumor type. On the 
other hand, BRAF mutation might be absent in certain types of gliomas. 
Furthermore, the incidence of BRAF mutations in non-glial CNS tumors has not 
been determined. Therefore, the original study is in need of extension to 
investigate the pattern of BRAF mutation in CNS tumors. 
Overexpression of EGFR or the truncated form EGFRvIII is common in 
primary GBM and is able to activate Ras. Since spontaneous activation of EGFR 
contribute to Erk phophorylation, oncogenic signal from EGFR might be 
transmitted through BRAF to downstream effectors. Also, disruption of either 
EGFR or BRAF mutation might be enough to disrupt mitogenic signaling pathway 
in tumor precursors. Knowledge of whether BRAF mutation in astrocytic tumors, 
if any, occurs mutually exclusively with EGFR amplification could provide 
additional clues on molecular pathogenesis of astrocytic tumors. 
Other than focusing on the newly discovered oncogene, mapping of critical 
regions harboring TSGs in astrocytic tumors is equally important. Total or partial 
loss of chromosome 14 was detected among 11 of 18 GBM and AA clones by 
cytogenetic analysis (Debiec-Rychter et al.，1995). In a genome-wide allelotype 
analysis on diffuse astrocytoma (fibrillary) and GBM, two CRDs were located to 
14q21.2-q32.12and 14q32.1 -q t e r (Hu et al.，2002). 
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Deletions in 14q are frequent in a variety of cancers. The cancers with CRDs 
between 14q21.2 - q32.12 include renal oncocytomas (Schwerdtle et al‘, 1997), 
gastrointestinal stromal tumors (El-Rifai et al., 2000), malignant mesothelioma 
(Bjorkqvist et al., 1999; de Rienzo et al‘, 2000), neuroblastoma (Hoshi et al” 2000; 
Thompson et al., 2001), meningioma (Simon et al., 1995; Tse et al., 1997) and 
nasopharyngeal carcinoma (Cheng et al., 1997; Mutirangura et al., 1998). 
There are 2 major aims in my research study. The first aim is to investigate 
whether BRAF alteration is involved in CNS tumors. To achieve this aim, the 
following objectives were raised: 
1. To investigate the pattern of BRAF mutations among CNS tumors. 
2. To examine B-Raf immunoreactivity in astrocytic tumors. 
3. To determine the correlation between EGFR amplification and BRAF 
mutation in astrocytic tumors. 
4. To determine the correlation between EGFR amplification and B-Raf 
immunoreactivity in astrocytic tumors. 
The second aim of the current study is to refine CRDs on 14q21.2 — q32.12 in 
astrocytic tumors by microsatellite analysis. 
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3. Materials and methods 
3.L Clinical materials 
A total of 201 CNS tumors comprising of 100 astrocytic tumors (23 
diffuse astrocytomas, 18 AAs and 59 GBMs (including 2 GSs), 31 
oligodendroglial tumors, 23 ependymal tumors, 21 MBs and 26 meningeal 
tumors were included in the current study. Diagnosis of tumor specimens 
was based on WHO criteria (Kleihues and Cavennee, 2000). All tumors 
and normal tissues examined in this study were collected from hospitals in 
Mainland China and Hong Kong (Anhui Provincial Hospital, Anhui; 
Beijing Hospital, Beijing; Hua Shan Hospital, Shanghai; Kwong Wah 
Hospital, Hong Kong; Prince of Wales Hospital, Hong Kong; Queen Mary 
Hospital, Hong Kong; Ren Ji Hospital, Shanghai; Sir Run Run Shaw 
Hospital, Hangzhou; The Second Hospital Nanjing Medical University, 
Nanjing; Tuen Mun Hospital, Hong Kong; West China Hospital, Sichuan 
University, Sichuan; Xiang Ya Hospital, Changsha). Clinical information 
of astrocytic and non-astrocytic CNS tumors examined in this study was 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2. Cell lines 
Ten cell lines were examined in the current study (Table 3.3). Six of them 
were derived from astrocytic tumors, including LNZ308, SKMG3, U138, U343, 
GBM2603 and GBM6840. The latter two lines were established in-house (Di 
Tomaso et al., 2000). SKMG3 was a gift from Dr. Joon Uhm, Department of 
Neurology, Mayo Medical School, Minnesota, U.S.A. The MB cell lines D283 
Med and Daoy were obtained from American Type Culture Collection (ATCC; 
Manassas, U.S.A.), while D384 Med was a generous gift from Dr. Darell Bigner， 
Duke Comprehensive Cancer Centre, North Carolina, U.S.A. The primitive 
neuroectodermal tumor (PNET) line, PFSKl was obtained from ATCC. 
75 
Table 3.3. Cell lines of CNS tumor origin examined in the current study. 
Tumor Type Cell Line 






Medulloblastoma D283 Med 
D384 Med 
Daoy 
Primitive neuroectodermal tumor PFSKl 
The squamous cell carcinoma line A431, also obtained from ATCC was used 
as control for B-Raf immunohistochemistry (Section 3.6) and quantification of 
EGFR gene dosage (Section 3.7). 
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3,3, Cell culture 
All cell lines, except D384 Med and PFSKl, were maintained in Minimum 
Essential Medium Eagle with alpha modification (Sigma-Aldrich Company, 
Missouri, U.S.A.) adjusted to contain 0.22% sodium and supplemented with 10% 
fetal bovine serum (FBS; HyClone Laboratories, Inc., Logan, Utah, U.S.A.) and 2 
mM L-glutamine (GIBCO, Japan). D384 Med was maintained in Richter's Zinc 
Option Minimum Essential Medium (GIBCO) with 0.22% sodium bicarbonate, 
10 mM HEPES and 20% FBS. PFSKl was maintained in RPMI-1640 medium 
(Sigma-Aldrich) adjusted to contain 0.15% sodium bicarbonate, 25 mM glucose, 
10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine and 10% FBS. All 
cell lines were kept at 37°C in a humidified atmosphere containing 5% CO2. 
2 
Cell passage was performed at 80% confluence in T75 (75 cm ) flask (Nunc, 
Roskilde, Denmark). Cells were washed with PBS to remove trypsin inhibitor 
present in FBS. Cell detachment was aided by incubation in 1.5 ml of 0.25% 
trypsin and 1 mM EDTA (GIBCO) at 37�C for 1 — 4 min. Trypsinization was 
stopped by the addition of 7.5 ml of complete medium. Cells were spun down at 
1200 rpm (Heraeus Sepatech model Megafuge 1.0) for 3 min and resuspended in 
15 - 20 ml of complete medium. For routine passages, cells were split 3- to 4-
fold and re-seeded in flasks. 
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3,4. DNA extraction 
DNA extracted from tumors, cell lines and constitutional blood 
samples was subject to mutation analysis of the BRAF gene, quantification 
of EGFR gene dosage and LOH analysis of chromosome 14q. The 
extraction methods for these three types of samples were essentially the 
same, except for sample pre-treatment. 
3.4.1. Pre-treatment of samples 
Ninety-three CNS tumors resected from patients were immediately snap 
frozen and stored at —80�C. A series of sections were cut from each tumor using 
Leica CM1800 cryostat at —18�C. The first section was cut to 4 |Lim thickness, 
stained with haematoxylin and eosin (H&E) and examined microscopically for 
tumor content by at least one pathologist. When the first section showed a 
minimum of 80% tumor content, 8 - 2 0 serial sections of 25-jum-thickness would 
then be cut and collected for DNA extraction. The last tissue section of 4 |Lim was 
also stained with H&E and examined microscopically to confirm tumor content. 
Frozen tissue matrix (OCT) was removed from tissues by repeated washings 
(usually three times) each with 1 ml of chilled phosphate-buffered saline (PBS), 
followed by centrifiagation at 3000 rpm for 4 min at room temperature using 
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microcentrifuge (Eppendorf Mini Spin, Hambury, Germany). After the third wash, 
the tissue pellets were rid of PBS and subject to DNA extraction. 
For formalin-fixed paraffin-embedded tissues, H&E-stained sections of 
available blocks were examined and about 20 consecutive 10-|Lim-tissue sections 
from the most representative one were cut and collected into microfuge tubes. 
Paraffin was removed by vigorous vortexing in 1.2 ml xylene, followed by 
centrifiigation at 13000 rpm for 4 min. To remove xylene, tissue sections were 
pressed down using pipette. After washing for three times, residual xylene was 
removed by gentle vortexing in 1.2 ml 100% ethanol, followed by centrifugation 
at 13000 rpm for 4 min. Tissue pellet was dried using the Speed Vac concentrator 
(Savant, U.S.A.). 
Tumor-matched blood samples, collected in EDTA-coated Vacuette(s) 
(Ejazuddin), were available in 33 cases and stored at -20°C. After thawing 
quickly at 37°C, 3 - 6 ml of blood was transferred into 15 ml polypropylene 
conical tube and the volume was brought up to 12 ml using chilled PBS. 
Lymphocytes were collected by centrifugation at 3200 rpm for 15 min at 4 � C 
(Eppendorf centrifuge model 5810R). Since heme of red blood cells is known to 
inhibit PCR, lymphocytes were repeatedly washed in PBS followed by 
centrifiigation until a clear supernatant was attained. 
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3.4.2. Cell lysis and protein removal 
To release DNA from cells, tissue pellet was suspended in 1 ml of lysis buffer 
(0.1 M sodium chloride, 0.05 M Tris-HCl, pH 7.4, 1 mM EDTA and 0.5% sodium 
dodecyl sulfate) containing 400 |Lig/ml proteinase K. Protein digestion was 
allowed to proceed at 54°C for a minimum of 6 hours. If tissue clumps remained 
observed after incubation, 20 — 40 \i\ of 10 mg/ml proteinase K (final 
concentration 200 — 400 |Lig/ml) was added to the mixture and protein digestion 
was allowed to proceed for another minimum of 6 hours at 54°C. 
When digestion was completed, as indicated by disappearance of tissue 
clumps in lysate, equal volumes of phenol/chloroform/isoamyl alcohol (PCI; 
25:24:1, v/v/v), equilibrated at pH 8, was added to extract protein. The mixture 
was shaken by hand for 10 min, chilled at -20°C for 10 min and centrifliged at 
13,000 rpm for 20 min. The cooling before centrifugation prevents release of PCI 
vapor and enables more complete separation of different liquid phases. The upper 
aqueous layer containing DNA was collected into new tubes for DNA 
precipitation. 
For lymphocytes and cell lines, cells were pelleted by centrifugation at 1200 
rpm for 3 min and lysed in 4 ml lysis buffer containing 100 |Ltg/ml proteinase K 
Protein digestion was performed at 54�C, followed by PCI treatment, as pre-
treatment of tumor tissues described above. 
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3.4.3. Precipitation of DNA 
DNA was salted out from the aqueous solution by addition of 1 /lO volume of 
3 M sodium acetate (pH 5.2) and 2 volumes of chilled 100% ethanol. In case no 
obvious DNA precipitate was observed after thorough mixing of solutions, 1 |li1 of 
1% glycogen was seeded. With or without appearing of precipitates, DNA 
precipitation was further aided by storing at -20°C overnight. DNA was 
recovered from salt solution by centrifugation at 13,000 rpm for 10 min. After 
complete aspiration of liquid traces, DNA was allowed to dry in air for 5 - 10 min. 
Colorless DNA pellet was suspended in 20 - 100 ]i\ of autoclaved Milli-Q water. 
Over-drying of DNA as indicated by reappearance of white color was avoided. 
To ensure even suspension, DNA was incubated at 54°C for 2 hours. 
3.4.4. Determination of DNA concentration 
One ]i\ of DNA was diluted in appropriate volume of water and its 
absorb an ce was measured at 260 nm, 280 nm and 320 nm using the GeneQuant 
spectrophotometer (Amersham Biosciences). DNA concentration in 昭/ml was 
calculated by: 
(absorbance at 260 nm — absorbance at 320 nm) x 50 xlO" x dilution factor. 
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Purity of DNA was estimated from the ratio of (absorbance at 260 nm — 
absorbance at 320 nm) to (absorbance at 280 nm - absorbance of 320 nm). 
Working DNA solution of 0.1 \ig/\i\ was prepared and stored at -20°C until use. 
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5.5. Mutation analysis of BRAF by cycle sequencing 
Exons 11 and 15 with their flanking sequences of the BRAF gene were 
sequenced for somatic base changes using the ABI Prism BigDye Terminator 
Cycle Sequencing Ready Reaction Kit version 2.0 (Applied Biosystems). 
3.5.1. Amplification of BRAF exons 
PCR was performed in a final volume of 25 |li1 containing 100 ng of genomic 
DNA, 0.75 Unit of AmpliTaq Gold DNA Polymerase (Applied Biosystems), 10 
mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl:, 200 jjM of 2，-
deoxynucleoside 5'-triphosphate, and 400 pM of each primer (Invitrogen, 
HKSAR, China) using the GeneAmp PCR system 2700 (Applied Biosystems). 
Primers were synthesized according to Davies et al., 2002. 
Sense primer of exon 11: 5'-TCCCTCTCAGGCATAAGGTAA-3 ‘ 
i 
Anti-sense primer of exon 11: 5 ‘ -CGAAC AGTGAAT ATTTCCTTTGAT-3, 
Sense primer of exon 15: 5 '-TC ATAATGCTTGCTCTGAT AGGA-3 ‘ 
Anti-sense primer of exon 15: 5' -GGCCAAAAATTTAATCAGTGGA-3 ‘ 
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PCR conditions included initial denaturation at 94°C for 10 min, followed by 38 
cycles of denaturation at 9 5 � C for 30 sec, annealing at 58°C for 30 sec and 
extension at 72°C for 1 min，and a final extension step at 72°C for 10 min. 
To confirm successful amplification, a 5-\i\ aliquot of each PCR product was 
subjectd to electrophoresis. After mixing with 1 |LI1 of 6X gel-loading buffer (25% 
of bromophenol blue, 0.25% of xylene cyanol FF and 40% of sucrose) DNA was 
loaded onto a 2% agarose gel containing 50 mM ethidium bromide. 
Electrophoresis was carried out in IX TBE buffer (0.09 M Tris, 0.89 M boric acid 
and 2 mM EDTA, final pH 8.0) at 120 V for 15 min. DNA bands were observed 
under ultra-violet illumination (UVP transillumniator; California, U.S.A.). For 
each sample that showed successful amplification, the remaining PCR product 
was purified using the High Pure PCR Product Purification Kit (Roche 
Diagnostics Limited, Germany) and eluted in 100 jul of elution buffer (5 mM Tris-
HCl, pH 8.5). The DNA was then concentrated into a volume of 5 |j1 using the 
Speed Vac concentrator. 
3.5.2. Cycle sequencing and automated gel electrophoresis 
Cycle sequencing was performed in a final volume of 5 |LI1 containing 1 - 2 \i\ 
of DNA template, 2 \i\ of 2.5X Big Dye Terminator reagent mix (Applied 
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Bio systems) and 160 pM of either forward or reverse primer (Invitrogen). Cycle 
sequencing commenced with an initial denaturation at 95°C for 2 min, followed 
by 46 cycles of denaturation at 96°C for 15 sec, annealing at 54°C for 15 sec and 
extension at 60°C for 3.5 min. 
Sequencing product was diluted to 20 \i\ with Milli-Q water and purified from 
unincorporated dye terminators using Sephadex G50 Fine (Amersham 
Biosciences) spin column. To prepare the spin column, well-suspended Sephadex 
G50 Fine beads were packed into 1.5 ml microspin columns and spun at 3,000 
rpm for 1 min. Product was applied to the center of packed column and subject to 
centrifugation at 3000 rpm for 1 min. Flowthrough was dried in the Speed Vac 
concentrator. Content was resuspended in 3.6 |li1 gel-loading buffer (a mixture 
containing 1 volume of 25 mM EDTA with 50 mg/ml Blue Dextran and 5 
volumes of deionized formamide), denatured at 95°C for 2 min and chilled on ice 
immediately to prevent re-annealing. 
To prepare the resolving gel, 25 ml of 4% denaturing polyacrylamide gel 
solution (3.8% acrylamide, 0.2% bis-acrylamide, 8.9 mM Tris, 8.9 mM boric acid 
and 0.2 mM EDTA and 6.0 M urea, pH 8.3; filtered through a 0.45 |um filter) was 
polymerized by addition of 125 |li1 of 10% ammonium persulfate and 12.5 \i\ 
N,N,N',N'-tetramethylelthylenediamine. The gel was allowed to polymerize for 
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at least one hour. After loading 1.2 ！liI of sequencing product into each lane of the 
gel, electrophoresis was carried out in the automated ABI Prism 377 DNA 
sequencer (Applied Biosystems). Data collected were analyzed using ABI 
sequencing analysis software version 3.7. 
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5.6. Immunohistoch emistry of B-Raf and GFAP 
3.6.1. Pre-treatment of samples 
In this and the following sections, washing in TBS refers to three times of 
washing in Tris-buffered saline (TBS; 50 mM Tris-HCl, pH 7.6 and 56.8 mM 
NaCl) for 5 min each. 
For formalin-fixed paraffin-embedded tissues, sections of 4 |Lim thickness 
were thoroughly dried in a vacuum-drying oven at 40°C (WTBBinder) and 
deparaffinized in three changes of xylene for 5 min each. Hydration was enabled 
by gradual changes through ethanol in decreasing gradient (100% ethanol twice, 
95% ethanol, 70% ethanol and distilled water for 5 min each). Antigen was 
retrieved from formalin in 1 mM EDTA (pH 8) by microwave treatment (850W 
for 3.5 min followed by 170W for 10 min). Slides were then cooled in running 
water and washed with TBS. Endogenous peroxidase activity was blocked by 
incubation in 0.3% hydrogen peroxide in TBS for 10 min. Slides were then 
washed in TBS again prior to primary antibody treatment. 
Thick sections of frozen tissues were prepared using scrap el under -18°C, 
fixed in 10% formalin overnight, embedded in paraffin and processed as 
described above. 
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For cell lines, 2 to 4 x 10^ cultured cells were seeded onto each cover-slip and 
allowed to grow for 1 - 2 days in 6-well plate (IWAKI, Japan) containing 2.5 ml 
of completed medium per well. Before immunohistochemistry, cells were washed 
twice with chilled PBS and fixed in chilled methanol for 10 min. Endogenous 
peroxidase activity was blocked by incubation in 1% hydrogen peroxide in 
methanol for 25 min. Slides were washed in TBS after 2 brief washes in distilled 
water for immunohistochemistry. 
3.6.2. Detection of B-Raf and GFAP antigen by ABC method 
All chemicals mentioned in this section were buffered in TBS. 
Tissues and cells were incubated in 5% normal rabbit serum (DAKO, 
Denmark) for 5 min to block non-specific protein regions for primary antibody. 
After drainage of extra rabbit serum, the mouse monoclonal anti-B-Raf in 3% 
BSA (Sigma) at 1 AO dilution was applied to sections. This antibody is specific to 
amino acids 12 — 156 of human B-Raf (Santa Cruz Biotechnology, California, 
U.S.A.). As negative control, 3% BSA was used. After overnight incubation at 
4�C, slides or cover-slips were washed in TBS, incubated in biotinylated rabbit 
anti-mouse antibodies (DAKO) in 0.03% BSA (at 1:200 dilution) for 40 min and 
washed in TBS. Next, they were incubated in streptavidin conjugated horseradish 
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peroxidase (ZYMED, U.S.A.) in 0.03% BSA (at 1: 400 dilution) for 45 min and 
washed in TBS. A solution of 2% DAB and 0.03% hydrogen peroxide was 
applied and color development was observed under the microscope. After a 
maximum of 20 min or when desired stain intensity was observed (approximately 
3 - 8 minutes), DAB was completely removed by thorough washing under tap 
water for 15 min. Tissues and cells were counterstained by hematoxylin for 7 min, 
processed through dehydrating alcohol series (70% ethanol, 95% ethanol, and 
100% ethanol twice) and three changes of xylene and mounted in PERMOUNT 
(Fisher Chemical, New Jersey, U.S.A.). 
Positive results were scored if the population of immunoreactive cells in a 
400X microscopic view was greater than 5%. Tumor cases with immunopositive 
cell population greater than 5% but equal to or lower than 15% were designated 
'+'. Those with immunopositive cell population greater than 15% but equal to or 
lower than 40% were designated '++，. Those with immunopositive cell ;  
population greater than 40% were designated ‘+++，. Otherwise, was recorded. 
Procedures for immunohistochemical staining of GFAP were similar to that 
of B-Raf. Polyclonal rabbit anti-cow GFAP antibody isolated from bovine spinal 
cord (DAKO, Denmark) at 1:500 dilution was used in place of mouse anti-B-Raf 
monoclonal antibody. Five % normal swine serum (DAKO) and biotinylated 
89 
swine anti-rabbit immunoglobulins (1:200 dilution; DAKO) were used for 
blocking non-specific protein interactions and as the secondary antibody. Positive 
results were again recorded for specimen harboring an immunoreactive cell 
population greater than 5% under a 400X microscopic view. 
3.6.3. Controls 
A431 cells were used as positive control for cultured cells, as recommended 
by Santa Cruz Biotechnology. Based on the detection of 97- and 62-kDa B-Raf 
proteins in neurons by Dugan et al. (1999), neurons in formalin-fixed paraffin-
embedded normal cerebrum from autopsy were used as positive control for 
paraffin-embedded specimens. 
Undetectable B-Raf expression in astrocytes was also reported by Dugan et al. 
(1999). In addition, B-Raf protein in muscle was barely detectable after 
i 
immunoprecipitation and Western blotting in Bamier et a/.'s study. Therefore, 
astrocytes in cerebrum autopsy were used as a negative control and skeletal 
muscle was collected to test the specificity of our antibody. 
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3.7. Quantification of EGFR gene dosage by TaqMan based real-time PCR 
'Real-time' here means the detection of PCR product during amplification 
without purification or gel electrophoresis separation of end-point product. 
TaqMan probes based on fluorescence resonance energy transfer were used for 
assay on gene dosage. Each probe includes a fluorescent reporter and a 
fluorescent quencher molecule at 5' and 3' end, respectively. During extension 
phase of PCR, the reporter is freed from the quencher by 5' to 3'-exonuclease 
activity of Taq polymerase. Fluorescence of the reporter molecule increases as 
products accumulate. Once a measurable change in the total fluorescence of the 
reaction mixture can be detected, fluorescence rises appreciably above the 
background. Such a point is noted as the threshold cycle (Ct). Upon and after this 
point, a linear relationship exists between the log of the starting amount of a 
template and its threshold cycle. Detection of unknown starting template amount 
is therefore enabled by plotting the log of different standards of the template ；: 
against their threshold cycles. 
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3.7.1. Preparation of gene constructs 
To prepare standards for EGFR, a fiill-length EGFR cDNA cloned into the 
pBluescript-SK plasmid was used. This plasmid was obtained from Dr. Webster 
K. Cavenee, Ludwig Institute for Cancer Research, San Diego, U.S.A. The full-
length EGFR cDNA gene covers nucleotide 63 — 3950 of the reference sequence 
NM_005228. 
To correct for minor variations due to differences in input DNA template 
during real-time PCR, quantification of EGFR for each sample was accompanied 
by quantification of the house-keeping gene, hetal-microglobulin (B2M), located 
at 15q21 — q22.2. The B2M gene construct was prepared by cloning a 90-bp 
fragment corresponding to part of exon 2 of B2M into the pCR2.1-T0P0 vector 
(Invitrogen). This fragment covers nucleotide 166 - 255 of the B2M reference 
sequence NM_004048. Briefly, the B2M fragment was amplified from genomic 
DNA of SKMG3, ligated to the pCR2.1-T0P0 vector and transformed into E. coli 
TOP 10 competent cells (TOPO TA Cloning Kit; Invitrogen) according to 
manufacturer's recommendation. A bacterial clone containing the pTOPO-万2M 
plasmid was isolated and the authencity of B2M insert was confirmed by 
sequencing. 
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Plasmid DNA of both EGFR and B2M was prepared using the Nucleoband 
AX plasmid purification kit (Macherey-Nagel, Duren, Germany). Plasmid 
concentration, determined using the PicoGreen ds DNA Quantitation kit 
(Molecular Probes Inc., Eugene, Oregan, U.S.A.) was expressed as number of 
copies/|il which was calculated according to the formula: 
DNA concentration in \igl\i\ x 10'^  
X Avogadro's number. 
Molecular weight of DNA fragment 
3.7.2. Primers and TaqMan probes 
Primers and TaqMan probes of EGFR and B2M used in real-time PCR were 
designed by Primer Express version 1.0 software (Applied Biosystems) and their 
sequences were listed in Table 3.4. For B2M, the same primer set was used in 
both cloning and real-time PCR. The TaqMan probes were labeled at the 5' end 
with 6-carboxyfluorescein (FAM) reporter dye and at the 3， end 
tetramethylrhodamine (TAMRA) quencher dye. All primers and probes were 















































































































































































































































3.7.3. Experimental condition and PCR program 
PCR mix was prepared in a final volume of 25 \i\ by combining 12.5 |li1 of 
100 ng DNA, 500 nM each of forward and reverse primer and 400 nM TaqMan 
probe with 12.5 of IX Platinum Quantitative PCR SuperMix-UDG mix 
containing 1.5 unit of Platinum Taq DNA Polymerase, 20 mM Tris-HCl (pH 8.4), 
50 mM KCl, 7 mM MGCB, 200 |LIM dGTP, 200 |LIM dATP, 200 ^iM dCTP，400 
|LIM dUTP and 1 unit of uracil DNA glycosylase (Invitrogen). A final 
concentration of 8 mM MgCl� was used in B2M PCR mix. To avoid PCR cany-
over contamination, DNA containing dUTP was digested by uracil DNA 
glycosylase at 50°C for 2 min. Enzyme was then inactivated at 95°C for 2 min 
(Longo et al., 1990). DNA amplification consisted of 45 cycles of denaturation at 
95°C for 30 sec and annealing/extension at 60°C for 1 min. 
To ftjrther avoid DNA cross-contamination, all PCR manipulations were 
carried out with Aserosol Barrier Tips (Continental Lab Products, California, 




3.7.4. DNA standards 
To construct standard curves for EGFR and B2M, a serial dilution of each 
plasmid DNA over the range of 10 - 10 copies were amplified and the Ct values 
obtained were plotted against the input copy number. 
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3.7.5. Controls 
The GBM cell line SKMG3 with endogenous EGFR amplification and the 
squamous cell carcinoma A431 with gain in EGFR copies were used as positive 
control for increased EGFR gene copy number, whereas patient blood samples 
were included as control for normal gene copy number. Milli-Q water was used 
in place of DNA in negative control. 
3.7.6. Experimental layout 
In each real-time experiment, 4-point standard curves of EGFR and B2M 
were included to correct PCR efficiency of each individual run, making inter-
assay comparison more reliable. Positive and normal controls, as well as the 
standards, were done in duplicate while samples were performed in triplicate. 
S 
; j ： 
i 
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3,8, Microsatellite analysis of chromosome 14q in astrocytic tumors 
Diffuse astrocytomas, AAs and GBMs were screened for LOH at 
chromosome 14q21.2 - q32.12, covering a genomic region of 48.1 Mb. Eighteen 
short tracts of single-copy polymorphic DNA sequences were selected from 
Marshfield genetic map (http://research.marshfieldclinic.org/genetics) and 
positioned according to the human genome sequence available at University of 
California at Santa Cruz (http://www.genome.ucsc.edu). 
Microsatellite markers with PCR product less than 250 bp were chosen for 
LOH analysis. Shorter PCR fragments are easier to be amplified, especially for 
DNA extracted from paraffin blocks, in which DNA is often fragmented. 
Markers with higher polymorphism based on the Genome Database 
(http://www.gdb.org) or appeared highly informative in previous studies were 
chosen. The 18 markers selected spaced at an average genomic interval of 2.8 Mb. S 
>1. 
I� 
Forward and reverse primers were synthesized by Invitrogen according to 
sequences available at the Genome Database. All forward primers were labeled at 
5' end with fluorochrome FAM, 6-carboxyhexafluorescein (HEX) or 6-
carboxyrhodamine (ROX). The use of different fluorochromes allows 
simultaneous loading of multiple products labeled with various fluorochromes 
onto a single lane for electrophoresis. PCR conditions were optimized by varying 
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annealing temperature, extension temperature, MgCb concentration, and addition 
of dimethyl sulfoxide (DMSO). Each PCR was performed in a volume of 20 |LI1 
containing 1 |LI1 of 0.1 \xg/\i\ working DNA, 0.5 Unit of AmpliTaq Gold DNA 
Polymerase, 100 mM Tris-HCl (pH 8.3), 500 mM KCl，2 mM MgCb, 200 i^M 
dNTP, and 200 pM of each primer (Invitrogen). DMSO (5% or 8%) was added in 
some mixes to enhance PCR specificity. PCR conditions included enzyme 
activation at 9 5 � C for 10 min and 38 cycles of 95�C for 30 sec, 57.5 — 65.9�C for 
30 sec and 72°C for 30 sec, as shown in Table 3.5. 
I ； 1 ！ 
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Table 3.5. PCR conditions of 18 microsatellite markers used in LOH analysis. 
Microsatellite Product Annealing Concentration of 
markers size temperature DMSO 
(bp) r c ) (%) 
D14S288 189-209 ^ -
D14S1068 211 - 2 2 5 61.5 8 
D14S978 2 0 0 - 2 5 8 63.7 -
D14S1057 151 - 169 61.5 -
D14S980 158- 184 63.7 -
D14S592 222 - 240 61.5 -
D14S997 204 - 220 57.5 -
D14S1026 118- 150 57.5 -
D14S1011 175 - 191 59.9 -
D14S588 117- 141 63.7 -
D14S77 203 - 2 5 1 59.9 -
D14S43 158 - 190 57.5 -
D14S61 197-227 65.9 -
D14S59 99 — 109 59.9 5 
D14S1000 107- 133 59.9 -
D 1 4 S 1 0 3 7 183 - 2 3 3 65 .9 -
D14S68 148 - 172 59.9 -
D14S280 229-241 57.5 -
Varying amount (Table 3.6) of PCR products with different fluorophore-
labels were concentrated using Speed Vac concentrator for 10 min, added with or 
without 0.5 [i\ of GS-HD400 ROX size standard (Applied Biosystems) and loaded 
onto gel. 
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Table 3.6. Amount of PCR products loaded onto denaturing gel. 
Fluorophore PCR product (jiil) ROX-labeled 100 bp size marker (|ul) 
FAM 3 0.5 
HEX 4.5 0.5 
ROX 5 -
Conditions of gel electrophoresis were basically the same as that described for 
DNA sequencing (Section 3.4.2). After addition of 4 jiil loading dye (1 volume of 
25 mM EDTA with 50 mg/ml blue dextran, 5 volumes of deionized formamide), 
product was denatured at 95°C for 10 min and chilled on ice immediately. One |jI 
denatured DNA was loaded onto 4% denaturing polyacrylamide gel (3.8% 
acrylamide, 0.2% bis-acrylamide, 8.9 mM Tris, 8.9 mM boric acid and 0.2 mM 
EDTA and 6.0 M urea, pH 8.3, filtered through a 0.45 [im filter, polymerized by 
addition of 125 ul of 10% ammonium persulfate and 12.5 |li1 N,N,N'’N，-
tetramethylelthylenediamine per 25 ml). Gel electrophoresis was performed again : 
in the automated ABI Prism 377 DNA sequencer. Results were analyzed using 
ABI Gene Scan analysis software version 3.7. 
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4. Results 
4, L Mutation analysis of BRAF 
Exons 11 and 15 of the BRAF gene were screened for base changes by direct 
cycle sequencing in 195 CNS tumors (Tables 3.1 and 3.2). The tumor series 
comprised of 23 diffuse astrocytomas, 18 AAs, 53 GBMs (including two GSs), 31 
oligodendroglial tumors, 23 ependymal tumors, 21 MBs and 26 meningeal tumors, 
and 10 cell lines including six from astrocytic tumors (GBM2603, GBM6840, 
LNZ308, SKMG3, U138 and U343), three from MBs (D283 Med, D384 Med and 
Daoy) and one from PNET (PFSKl). 
The primers for exon 11 and exon 15 generated PCR products of 313 and 224 bp, 
respectively. Since these fragments were relatively short, sequencing was performed 
in one orientation. Upon detection of base change, sequencing of a newly amplified 
fragment was performed in both orientations. 
Sequencing signals translated to base sequence were aligned with BRAF 
referenced sequence (NT—007914) using the BLAST engine provided by the National 
Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html). A total of 14 types of ammo 
acid change have been reported in both exons 11 and 15. Out of them, the T1796A 
101 
substitution in exon 15 leading to V599E was detected in one GBM case BJIO and in 
two GBM cell lines, GBM2603 and GBM6840. Sequence electropherograms of 
exon 15 of all three cases showed a heterozygous T/A at the 1796 position of BRAF. 
Detection of an A signal in addition to the T signal indicated mutation in at least one 
allele. 
In the GBM case BJIO (Figure 4.1), signals given by the wild-type allele and that 
given by the mutant allele were of similar height. These results indicated mutation in 
one allele of the BRAF gene. Somatic mutation in BJIO was confirmed by no such 
base substitution in corresponding blood sample of the same patient. 
In GBM6840 (Figure 4.2), heterozygous T/A peaks at the 1796 position were 
also observed. In the sense strand, an A signal was always accompanied by a weaker 
T signal. The reverse was true in the anti-sense strand. In both sense and anti-sense 
strands, the peaks resulted from mutant allele were at least two folds of those resulted 
from the normal allele. It was suspected that multiple copies of chromosome 7 were 
present in this cell line. Since GBM6840 is an in-house established cell-line, 
karyotype of the cell line is available. In 79 metaphase spread of chromosomes, the 
number of chromosome 7 ranged from 2 to 4 copies, giving a mean of 3.1 and 
standard deviation (SD) of 0.6. Therefore, the higher peak signal of mutant allele 
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In GBM2603 (Figure 4.3), double peaks at the 1796 position were also observed. 
In the sense sequence, an A signal was always accompanied by a weak T signal, 
which was slightly above the background. The present of T signal was reproducible 
in the anit-sense strand as a weak A signal. This indicated the presence of normal 
allele instead of random background signal. Karyotype of GBM2603 is also 
available. Analysis of 49 metaphases showed 3 to 7 copies of chromosome 7, giving 
a mean of 4.8 士 0.7 copies. Considering results from karyotyping study, a much 
higher mutant to normal allele ratio in GBM2603 than GBM6840 indicated the 
presence of more mutant copies of chromosome 7 in GBM2603 than GBM6840. 
All results showing base changes were confirmed by repeating PCR and 
sequencing of both sense and anti-sense strands. In all other tumors, no base change 
in the 1796 position of BRAF was observed. Direct sequencing revealed no mutation 































































































4,2, Immunohistochemistry of B-Rafprotein 
The specificity of the anti-B-Raf antibody was tested by performing 
immunohistochemistry on the B-Raf expressing cell line A431, and on 10 normal 
brain and 2 skeletal muscle specimens. In concordance with the information provided 
by the anti-body supplier, cytoplasm of A431 cells were stained brown and appeared 
as rings around blue hematoxylin counterstained nuclei. In all brain specimens, 
brown triangular cytoplasm of neuron cell bodies with protruding axons were shown 
clearly above the background (Figure 4.4). In contrary, no 'star-shaped' astrocytic 
cells could be observed in any of the brain specimens. To confirm the presence of 
astrocytes which were non-reactive to anti-B-Raf antibody, consecutive brain 
specimens were stain by GFAP. Instead of neurons, brown normal astrocytes were 
shown up in the GFAP series. Lastly, none of the two muscle specimens showed 
brown color comparable with those of neuron cells and A431 cells. Therefore, the 




















































































































































































































































































To investigate whether B-Raf was abnormally expressed in astrocytic tumors, 
immunohistochemistry for B-Raf expression was then performed in 25 GBMs, 13 
AAs and 9 diffuse astrocytomas from the BRAF mutation study, in which tissues were 
available, and in the six glioma cell lines. B-Raf immunopositivity in tumor tissue 
was defined by possession of B-Raf immunopositive cells in greater than 5% of the 
total cell population in at least one 400X microscopic view. While all glioma cell 
lines were 100% B-Raf immunopositive (Figure 4.5), only 29.8% of astrocytic tumor 
cases possessed more than 5% of immunopositive cells (Table 4.1). 
Positive cases existed in all three grades of astrocytic tumors. Out of 9 diffijse 
astrocytomas, 4 (44.4%) possessed B-Raf immunoreactivity (Figure 4.6). While two 
specimens were comprised of 15 - 40% immunopositive tumor cells, the other two 
were comprised of 5 - 15% and at least 40% immunopositive tumor cells, 
respectively. Out of 13 AAs, 3 (30.8%) of them were B-Raf immunopositive (Figure 
4.7). Two specimens showed 5 — 15% B-Raf immunopositive tumor cells and the 
remaining one showed 15 — 40%. Lastly, 7 of 25 GBMs (28.0%) showed positive B-
Raf immunoreactivity (Figure 4.8). Two specimens were consisted of 5 - 10% B-Raf 
immunoreactive cells. One specimen showed 15 — 40% B-Raf immunoreactive cells. 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Using Fisher's exact test, correlation analysis of B-Raf immunoreactivity versus 
patient age, sex and tumor grade were performed. Patient age ranged from 4 to 76 
with a mean at 46.18 and a SD of 19.62. Grouping patients by older/younger than 18 
years did not reveal difference m B-Raf immunoreactivity between adults and 
younger patients (P 二 1.000). Since the first, second and third quartiles of patient age 
lay on 34, 42 and 65 years respectively, correlation analyses were repeated after 
grouping patients by older/younger than 34, 42 and 65 years. However，correlation 
between B-Raf immunoreactivity and patient age was still not observed (P 二 1.000, 
0.749 and 0.698 respectively). Also, no statistical correlation was detected between 
B - R a f immunoreactivity and sex (P 二 0.525). Thus, B - R a f immunoreactivity was not 
associated to both age and sex. 
Tumor cases with positive B-Raf immunoreactivity could be divided by 
possession of different proportion of immunopositive cells (Table 4.1). No apparent 
difference m i m m u n o p o s i t i v i t y m relation to tumor grade could be observed. Fisher's 
exact test was performed to investigate whether difference m B-Raf immunoreactivity 
(.versus at least one +) exist among tumors of different grade. My results did not 
show any statistical difference in B-Raf immunoreactivity between diffuse 
astrocytoma and AA (P = 1.000), between diffose astrocytoma and GBM (F 二 1.000), 
and between AA and GBM (- verse at least one 1.000). Lastly, AA and GBM 
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cases were sorted into high-grade group in comparison with low-grade diffuse 
astrocytoma. Statistical association between tumor grade and B-Raf 
immunopositivity was still not found using Fisher's exact test (P = 1.000). Therefore, 
B-Raf immunoreactivity of astrocytic tumors was not related to histological grading. 
To increase sample size for correlation study in later section (Section 4.4 and 4.5), 
B-Raf immunohistochemistry was performed for 6 additional GBM cases known to 
possess EGFR amplification in another project of our group but not included in 
mutation analysis of BRAF. All 6 samples showed negative B-Raf immunoreactivity. 
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43, Quantification of EGFR gene dosage 
To establish real-time technique in the current study, serial dilutions of 5 EGFR 
standards (from 3 x 10^ to 3 x 10^ copies/|^l) and 5 B2M standards (from 2 x 1 t o 2 
X 10^ copies/|Lil) were prepared. The house-keeping B2M gene was used to normalize 
cellular EGFR gene copies. Since the literature did not reveal abnormalities in B2M 
within astrocytic tumors, two copies of B2M were assumed in every normal or tumor 
cell. Threshold for gene quantification was calculated by 10 times average SD from 
as much baseline cycles as possible (Freeman et al., 1999; Giulietti et al., 2001; Heid 
etal, 1996). 
In amplification of EGFR, fluorescence signal raised above background beyond 
cycle 19 (Figure 4.9). Therefore, calculated threshold for EGFR gene quantification 
was 21.45 (10 times average SD from baseline cycles 2 to 19). Threshold cycles 
decreased linearly with log of input EGFR quantity (from 2 x 10^ to 2 x 10^ copies, 
duplicate trials; correlation coefficient = 0.999, Figure 4.10). Similarly, detectable 
fluorescence signal change was beyond cycle 16 for B2M and threshold was taken at 
19.82, which was calculated by 10 times average SD from baseline cycles 2 to 16 
(Figure 4.11). Threshold cycles also decreased linearly with log of input B2M 













































































































































































































































































































































































































































































































































































































































































































































To validate the real-time assay for EGFR quantification, DNA from the two 
EGFR overexpressmg cell lines SKMG3 and A431, and 10 patient's blood samples 
were recruited. A water blank was used as the negative control. From standard 
curves of the same experiment, starting quantities of EGFR and B2M of each sample 
in triplicate trials were defined and averaged to obtain the means of starting quantity 
(MSQs). Then an EGFR index was calculated by MSQ o让GFR over MSQ of B2M. 
In lymphocyte DNA from 10 patients, averaged EGFR gene index from three 
trials ranged from 1.0 to 1.7, averaged at 1.4 with a SD of 0.3. Normal range of 
EGFR index was then defined as 0.9 to 1.9 (mean 士 2 SD, Table 4.2). Samples with 
EGFR index greater than 1.9 but below 5.7 (calculated by 1.9 /2 x 6，indicating the 
presence of 6 copies) were regarded as gam in EGFR gene dosage. EGFR gene 
amplification was considered for those with EGFR index greater than 5.7. Averaged 
EGFR index from 3 trials of SKMG3 and A431 were 17.9 and 5.0 respectively, as 
determined from the 5-point standard curves in the same run. They were much higher 
above the lower limit (1.9) of normal dosage. Real-time experiments for 


















































































































































































































































































































































































































EGFR gene status was determined from samples included in BRAF mutation 
screening experiments, m which DNA were available. The series included 18 GBMs 
and 14 AAs, and 6 glioma cell lines. Triplicate trials were done for each case. Each 
experiment included four-point standard curves for EGFR and B2M respectively, 
SKMG3 as positive control, two normal blood controls and water as negative control. 
In the current series, EGFR gam was detected in one AA and two GBMs. 
Averaged EGFR index of the AA case WC114 was 3.1. Those of the two GBM cases 
WC159 and WN58 were 3 and 2.4, respectively. EGFR dosage of 6 GBMs included 
in the BRAF mutation screening experiments had been obtained in another study 
(Table 3.1). Including these samples, EGFR gam was detected m 7.1% (1/14) of AA 
and in 8.3% (2/24) of GBM. 
In the present study, EGFR amplification was also detected in one AA and 5 
GBMs. The AA case WC114 possessed an averaged EGFR index of 20.1. EGFR 
index of the GBMs ranged from 10.5 to 56.7 (Table 4.3)，with the median being 18.2. 
One of the 6 GBMs with EGFR index quantified in the other study was 29.4. (In that 
study, EGFR index of 10 lymphocyte DNA samples ranged from 0.7 to 1.5, those for 
SKMG3 and A431 were 17.7 and 4.3, respectively.) Including the 6 additional 
GBMs, EGFR amplification in AA and GBM were 7.1% (1/14) of AA and 25% (6/24) 








































































































































































































































































































































































































































































































































































Positive results in the current study were confirmed by another set of triplicate 
trials. All experiments were valid with respect to EGFR gene index of SKMG3 
(ranged from 15.3 to 24.3), normal blood control (0.9 to 1.4 and 1.0 to 1.9 
respectively) and negative control obtained in the same experiments. 
From karyotyping of cell lines GBM2603 and GBM6840, multiple copies of 
chromosome 7 were observed. However, gain in EGFR was not detected by real-time 
PCR. In GBM6840, the EGFR index of 1.1 was attributed to a near triploid pattern in 
representative metaphases (Di Tomaso et al., 2000). Analysis of 79 cells in 
metaphase showed the copy number of chromosome 7 varied from 2 to 4 and that of 
chromosome 15 ranged from 1 to 4. Averaging the ratio of the number of 
chromosome 7 to the number of chromosome 15 produced a mean at 1.1 with a SD of 
0.5. 
Similar to GBM6840, gain in EGFR in GBM2603 was missed out in real-time 
PCR. However, ratio of the number of chromosome 7 to the number of chromosome 
15 averaged at 2.2 with a SD of 0.9 as revealed by karyotyping and was higher than 
the EGFR index given by real-time PCR (1.6). Different with GBM6840, aneuploidy 
was not observed in GBM2603. Analysis of 49 metaphases showed 3 to 7 copies of 
chromosome 7 and 1 to 3 copies of chromosome 15. The deviation between ratio of 
number of chromosome 7 to number of chromosome 15 and EGFR index in 
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GBM2603 was probably due to the large variation in the number of specific 
chromosome among cells which was vulnerable to changes during cell passage. Of 
course, the possibility of gain in chromosome 7 without a parallel gam in EGFR 
dosage could not be ruled out. 
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4,4, Correlation between EGFR dosage and BRAF mutation 
In the current experiment, three GBM cases demonstrated BRAF mutation. The 
tumor sample BJIO displayed EGFR index in the normal range {EGFR index = 1.5) 
whereas the other 2 samples were GBM-derived cell lines, GBM6840 and GBM2603 
{EGFR indexes = 1.1 and 1.6, respectively). EGFR gene amplification and BRAF 
mutation occurred mutually exclusively in the GBM case BJIO. However, among 
tumor specimens, statistically significant correlation between BRAF mutation and 
gain in EGFR was not found (Fisher's exact test, P = 1.000). The same was true 
between BRAF mutation and amplification in EGFR (P 二 1.000). 
The GBM cell lines were not included m the above correlation analysis between 
EGFR gene dosage and BRAF mutation. Firstly, amplified gene sequences are 
carried primarily on double-minute chromosomes (Sauter et a/., 1996) which are 
always lost on primaiy culture (Humphrey et al, 1988). Secondly, cells with growth 
advantage on the culturing environment could be selected out and the cell population 
might not represent their original tumor specimen. Therefore, EGFR status in cell 
line might not be the same as in the original tumor. 
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5. Correlation between EGFR dosage and B-Raf expression 
To increase sample size of tumor harboring EGFR amplification，6 GBM cases 
known to process EGFR amplification from previous project but not included in 
BRAF mutation screening experiments were also included (Table 3.1). All together, 
15 astrocytic tumors with normal EGFR gene dosage, 3 (10%) with gam oi EGFR 
gene dosage and 12 (40%) with EGFR amplification were recruited for correlation 
study between EGFR gene dosage and B-Raf immunoreactivity. 
Among the 30 astrocytic tumors examined, 23 cases were negative in B-Raf 
immunoreactivity. EGFR amplification was detected in 52.2% of them. On the other 
hand, all 7 B-Raf immunopositive cases did not harbor EGFR amplification. 
Statistically significant differences in B-Raf immunoreactivity were found between 
tumors (all grades) with normal EGFR gene status and tumors with EGFR 
amplification (P = 0.047), and also between tumors with gain in EGFR gene and 
tumors with EGFR amplification (P = 0.029). Statistical significant differences were 
also found within GBM samples. That is between GBM tumors with normal EGFR 
gene status and GBM tumors with EGFR amplification (P = 0.029)，and between 
GBM tumors with gain in EGFR gene and GBM tumors with EGFR amplification (P 
=0.033). 
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Overall, B-Raf immunoreactivity in samples with EGFR amplification was 
significantly different from samples with normal or gain in EGFR status as examined 
by Fisher's exact test (P = 0.024). Highly significant association of negative B-Raf 
immunoreactivity and EGFR amplification within GBM was revealed by a P value of 
0.008. Astrocytic tumors with EGFR amplification did not harbour B-Raf 
immunoreacitivty. 
No statistical significant differences in B-Raf immunoreactivity existed between 
samples with normal EGFR gene status and samples with increased EGFR copies 
(gain or amplification), both in consideration of all samples (F = 0.235), in inclusion 
of AA only (P 二 1.000) and in employment of GBM only (P = 0.131). Significant 
difference in B-Raf immunopositivity was not detected between tumors with normal 
EGFR gene dosage and tumors with gain in EGFR gene both in consideration of all 
cases (P = 0.528) and in GBM only (F = 1.000). In other words, astrocytic tumors 
with normal or gain in EGFR dosage could possess B-Raf immunoreactivity, and the 
probability of possessing B-Raf immunoreactivity did not differ statistically between 
them. While the 2 GBM cases (WC159 and WN58) harboring gam in EGFR gene 
dosage were positive in B-Raf immunoreactivity, the AA case WC114 with EGFR 
gain was negative in B-Raf immunoreactivity. 
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4.6, Microsatellite analysis of chromosome 14q in astrocytic tumors 
To refine the 14q chromosomal loci that may contain tumor suppressor(s), a total 
of 12 diffuse astrocytomas, 5 AAs and 13 GBMs (including 2 GSs), and peripheral 
blood from the same patient were subject to LOH study. Patient ages ranged from 23 
to 72, with an average of 45.9 years. The male/female ratio was 1.6 to 1. 
Sixteen of 18 microsatellite markers generated informative results in 66% — 90% 
of cases. Two microsatellite markers of less informative were D14S1068 and 
D14S59, giving informative results m only 38% and 56% of cases, respectively. 
For heterozygous loci, LOH value was defined as allelic ratio of tumor tissue 
being normalized by allelic ratio of normal tissue and was calculated by 
(T1/T2)/(N1/N2), where 
T1 is the peak height of the tumor allele having the weaker signal peak, 
T2 IS the peak height of the other tumor allele having the higher signal peak, 
N1 is the peak height of the normal allele corresponding to that of Tl, 
and N2 is the peak height of the normal allele corresponding to that of T2. 
Taking the criteria of LOH as losing one of two alleles in more than 50% of tumor 
population and assuming 20% normal cell contamination, LOH would be indicated by 
a value of less than 0.6 or greater than 1 /0.6 or 1.67. For example, assuming 100 
131 
cells in tumor tissue, lost of allele A，if signal generated from allele B equaled 100 
unites, signal resulted from A would be equaled to 20 + 80 x 50% units. Allelic ratio 
would be given by division of A by B and is equal to 0.6. Therefore, an LOH value 
of 0.6 or less indicates loss of the allele with lower peak signal in 50% or more of 
tumor population. An LOH value of 1.67 or more indicates loss of the other allele. 
The above calculations did not take the difference in PCR efficiency of the two alleles 
into account. The actual allelic ratio had to be normalized by the allelic ratio of 
normal DNA from the same patient. 
LOH was detected in 9 of 32 astrocytic tumors. They appeared in 4 of 12 diffuse 
astrocytomas (33%), 2 of 5 AAs (40%), 3 of 13 GBMs (23%). The diffuse 
astrocytoma case WN66 (Figure 4.13) and WClOl showed LOH in all the 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The remaining two diffuse astrocytoma cases showed interstitial LOH pattern. In 
WN12 (Figure 4.14), LOH was found m D14S588, the marker next to D14S77 m this 
study, and in D14S1037, In NJ125 (Figure 4.15), LOH was detected only in D14S61 
(confirmed by triplicate trials). The flanking markers of all three single locus with 
LOH (D14S588 in WN12; D14S61 in NJ125; D14S1037 in WN12) showed ROH. 
In the AA case NJ5, all informative alleles centromeric from and including 
D14S61 showed LOH, while the 4 most distal loci (D14S1000, D14S1037, D14S68 
and D14S280) showed ROH. The marker D14S59, telomeric from D14S61 and 
centromeric from D14S1000，was non-informative. The AA case WC114 also 
showed LOH at the centromeric end and had retention of both alleles at the 5 most 
distal loci, including D14S59. D14S61 and D14S43, the markers centromeric from 















































































































































































































































































































































































































































































































































































































































































































































































All 3 GBM cases, including the GS variant, showed interstitial LOH. WC121 
harbored LOH in the centromeric region of the long arm of chromosome 14, starting 
from D14S997, and in the telemetnc region starting from D14S1037. Within the 
central ROH region of WC121, LOH was also detected in a single locus，D14S588. 
Single loss in this locus was seen also in the diffuse astrocytoma case WN12. 
D14S1000，the marker next to D14S1037, formed the LOH boundary in both WC121 
and WN12. Similarly, the marker D14S1026 next to D14S997 in WC121 acted as a 
flanking marker in both WC121 and N J l l l . D14S997 was the only locus showed 
LOH in N J l l l , confirmed by triplicate trials (Figure 4.16). The other flanking 
marker of LOH locus m N J l l l wasD14S592. 
Because of limited amount of available DNA in the GS case W C l l l , not all loci 
were investigated for LOH between D14S288 and D14S280. LOH was detected in 
D14S1026, with flanking ROH markers being D14S1057 and D14S1011. The LOH 














































































































































































































































Based on the LOH pattern in tumors with interstitial LOH loci or with LOH 
region in partial arm of chromosomal 14q, four CRDs could be defined (Figure 4.17). 
CRD 1 was mapped between D14S592 and D14S1026. In N J l l l , ROH was detected 
in consecutive loci centromeric from D14S997 starting from D14S592 and in 
consecutive loci telomeric from D14S997 starting from D14S1026. ROH in 
D14S1026 and the more telomeric marker D14S1011 was also detected in WC121. 
D14S997 gave the highest percentage of LOH (21.7 %) among all markers except 
D14S1068, for which informative rate was only 38 % (Figure 4.18). 
CRD2 was defined between D14S1011 and D14S77. The marker D14S588 
showed LOH singly in WN12 and WC121, with ROH in at least two consecutive loci 
m each flanking boundary, starting centromeric from D14S1011 or telemetric form 
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CRDS was defined by markers D14S43 and D14S59. The marker between the 
two flanking boundary showed LOH singly in D14S61 of NJ125. ROH in markers 
telomeric from D14S61 was also noted in the two AA cases showing partial deletion 
of the 14q in all informative markers centromeric from D14S59. 
CRD4 was defined by LOH at D14S1037 and ROH at D14S1000 in WN12 and 
WC121, and ROH at D14S68 in WN12. D14S280 as flanking locus is further 
supported by a previous GBM case (case 3) in Hu et al., 2002. 
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5. Discussions 
5•人 BRAF mutations as common events in human cancers 
BRAF mutations in human cancers were discovered only recently. Except in 
gliomas, BRAF mutations in all other cell lines being examined in Davies et a/.'s 
study were confirmed in tumor specimen of the same type in the same or in later 
studies. Dysplastic tissues and cancers with high BRAF mutation frequencies (Table 
1.3) included melanocytic nevi and melanoma (more than 60%; Brose et al, 2002; 
Davies et al., 2002; Pollock etal., 2003), papillary thyroid cancer (46%; Cohen et al., 
2003; Scares et al., 2003; Kimura et al., 2003)， cholangiocarcinoma (21.7%; 
Tannapfel et al., 2003), hyperplastic polpy (33.3%; Yuen et al., 2002) and colorectal 
carcinoma (12.1%; Davies et al., 2002). Less frequent (below 5%) mutations were 
also found in non-papillary thyroid cancer (Cohen et al., 2003; Kimura et al., 2003; 
Scares et al, 2003), colorectal adenoma (Yuen et al, 2002), ovarian cancer (Davies 
etal, 2002; Gemignani etal, 2003), head and neck squamous cell carcinoma (Cohen 
et al, 2003; Davies etal., 2002), lung cancer (Brose etal, 2002; Cohen etal, 2003; 
Naoki etal., 2002) and sarcoma (Davies etal., 2002). 
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5.2 BRAF mutations in CNS tumor specimens 
Although 10.5% glioma cell lines were found to harbor BRAF mutation, no 
mutation was detected among 15 glioma specimens. Compared with specimens of 
other tumor types, the number of glioma cases examined was relatively low. 
Therefore, frequency of BRAF mutation resulted from these glioma samples might 
not be representative (Davies etal., 2002). 
Glioma comprises of 3 major types of tumors. Histologically, they are classified 
into astrocytic tumors, oligodendroglial tumors and ependymal tumors. Each of these 
tumor groups contains several histological variants. It would be more useful to 
analyze the frequency of BRAF mutation in separate glioma types. Considering the 
presence of BRAF mutation in a wide variety of cancers, it is attractive to expand the 
glioma series to include a larger number and variety of CNS tumor samples. 
To investigate the pattern of BRAF mutation status in CNS tumors, 195 CNS 
tumor samples and 10 cell lines were recruited in the current study. Astrocytic 
tumors represent approximately 25% of all primary intracranial neoplasms. However, 
they constituted half of the samples examined in this study, including GBM in half of 
them. Astrocytic tumors were the focus of the current study because treatment of 
GBMs is difficult and patient survivals rarely go beyond two years. Therefore, any 
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role of BRAF alterations in tumorigenesis of astrocytic tumors might provide 
additional therapeutic targets. 
In Davies et al.�study (2002), a total of 545 tumor cell lines, comprising of 18 
human cancer types, were included for BRAF mutation screening. Interestingly, all 
mutations found, including those in glioma cell lines, were located within exon 15 
and exon 11, with a single mutation, the T1796A substitution in exon 15 constituting 
80% of total mutations. Hence, mutations of BRAF in exons 11 and 15 were regarded 
as the regions with highest mutation frequencies in human tumors. In this study, I 
used the direct sequencing approach to screen for BRAF mutations on exons 11 and 
15 in CNS tumors. 
My results showed BRAF mutations in 1 of 53 GBM cases and 2 (GBM2603 and 
GBM6840) of 6 GBM cell lines. Mutations in all three cases were heterozygous 
T1796A base substitution. Pattern of heterozygous mutations were commonly 
observed in other studies. For example, 30 of 32 colorectal tumors harboring BRAF 
mutations were heterozygous (Rajagopalan et al., 2002). Of note were the imbalance 
peak heights of wild-type and mutant alleles in the two GBM cell lines. Karyotypes 
of both cell lines showed more than one copy of chromosome 7. Combining 
karyotyping and sequencing results, the number of mutant alleles was higher than that 
150 
of normal alleles. Increase in mutant copies of BRAF in our cell lines suggested that 
gain in mutant copies may provide growth advantage to tumorigenesis. 
An increase in copy number of the BRAF gene had not been proposed in other 
tumors. However, increased copy of chromosome 7 is common in melanoma. 
Application of FISH to 7 primary malignant melanomas revealed trisomy in all 7 
cases in D'Alessandro et al.'s study (1997). Another FISH study revealed gam of 
chromosome 7 in 40.9% of malignant melanomas cases which included 14 primary 
and 8 metastatic ones (Matsuta et al., 1997). More recently, the number of 
chromosome 7 copies was determined in short-term primary cell cultures of nevi， 
primary melanomas, and metastases. The highest fraction of cell nuclei with more 
than 2 copies of chromosome 7 was detected in the group of metastases (Udart et al, 
2001). Gain of chromosome 7 was also suggested to be a significant aberration in the 
tumorigenesis of colonic carcinomas in which no endoreduplication has occurred 
(Herbergs et al., 1996). Nevertheless, B-Raf expression had not been reported in 
these tumors. We do not know whether they also harbor increased mutant copies of 
the gene. 
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Mutation in astrocytic tumors is less frequent than in tumors like melanoma, 
papillary thyroid cancer, cholangiocarcinoma and colorectal cancer. This suggests 
the relation of mutation in the BRAF gene to tumorigenesis in a minor astrocytic 
tumor subset. It is hard to tell whether mutation was exclusive in the most malignant 
end-point due to the scarcity of mutations in the astrocytic tumor type and the 
inclusion of fewer lower-grade astrocytic tumor samples. 
BRAF mutation was not detected in all other CNS tumors, including 31 
oliogodendroglial tumors, 23 ependymal tumors, 21 MBs, 25 meningeal tumors, 3 
cell lines from MB and 1 cell line from PNET. Thus, mutation in the BRAF gene is 
not a major genetic abnormality in non-astrocytic CNS tumors. 
5.2.1. Tumorigenic effect of the V599E substitution 
The V599 amino acid residue at B-Raf is conserved among the three Raf proteins 
(Figure 1.4). Two functional assays of B-Raf mutants were reported in Davies et al.'s 
study. Firstly, Myc-epitope-tagged expressions of cDNAs containing different 
mutations were transiently expressed in COS cells, immunoprecipitated using the 
Myc-tag and examined in kinase cascade assay. Compared with cells harboring wild-
type BRAF, BRAI^蕭 
mutant cells had elevated basal kinase activity of 10.7 folds. 
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Similar to cells with wild-type BRAF, BRAF^霊 mutant cells were also able to 
activate endogenous Erk (Davies etal., 2002). 
Secondly, epitope-tagged cDNA constructs of mutants was transfected into 
NIH3T3 cells to assay their focus-forming ability. ^^^ then found to be 
70 — 138 times more efficiently than wild-type BRAF in transforming activity. 
Treatment of V599E mutant tumor cell lines with the Mekl/2 inhibitor, which 
inhibited DNA synthesis, resulted in at least 80% blockage of Erk 1/2 phosphorylation 
(Davies et al, 2002). In another study, knock down of BRAF^^^^^ expression 
completely abrogated transformation as assessed by colony formation in agar 
(Hmgorani et al., 2003). Therefore, activating signals from B-Raf, at least m part, 
acts through the classical Ra£Mek/Erk cascade to promote proliferation. 
A role in tumor initiation by BRAF mutant had been proposed in melanoma 
studies. BRAF mutation was a frequent event in atypical and malignant melanocytic 
lesions of the skin (Uribe et al‘, 2003). Detection of high BRAF mutation frequency 
in benign lesions suggested the inadequacy of B-Raf in tumor initiation. Either 
abnormalities in addition to BRAF mutation were required for tumor initiation or the 
BRAF mutation was related to other tumorigenic events. Later, the detection of 
BRAF mutation in only 10% of the earliest stage or rapid-growth-phase melanoma by 
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Dong et al. (2003) further supported a role of B-Raf mutant in tumor progression 
rather than initiation. 
5.2.2. V599E B-Raf mutant activation independent of Ras activation 
Both Ras and B-Raf are members of the Ras/Raf/Mek/Erk signaling pathway. 
Mutation of either gene may produce similar effects. In Davies et al.'s study, Ras-
neutralizing monoclonal antibody did not block cell proliferation of BRAF^^^^^ 
mutant cell lines. This indicates the uncoupling of BRAF^^^^^ mutants from their 
proliferation requirement of Ras. 
Mutation pattern of the RAS and BRAF genes in the same tumor samples had been 
studied in many tumors, but no simultaneous mutations of the RAS genes and V599E 
mutation in BRAF in tumors have been detected so far. Mutually exclusive mutation 
patterns of RAS mutations and BRAF mutation of T1796A in the same tumors were 
present in colorectal cancers (Rajagopalan et al., 2002; Yuen et al., 2002), melanoma 
(Pollock et al., 2003), non-small cell lung carcinoma (Brose et al., 2002), 
micropapillary ovarian serous carcinomas and serous borderline tumors (Singer et al., 
2003) and papillary thyroid carcinoma (Kimura et al., 2003; Scares et al., 2003). 
In astrocytic tumors, mutation of the RAS gene is rare (Bos 1989; Bredel and 
Pollack, 1999; Gomori et al, 1999; Guha 1997). Evaluation of mutation status of 
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both the RAS and BRAF genes may not yield significant results. In considering 
mutually exclusive mutation pattern in the tumors mentioned above, BRAF^^e 
mutant m astrocytic tumors is likely to be capable of activating downstream members 
independent of Ras stimulation and plays a role in tumorigenesis. 
5.2.3. Autocrine stimulation of Ras signaling in V599E B-Raf mutant 
Despite the higher kinase activity of V599E B-Raf mutant compared with wild-
type B-Raf being activated by H-Ras^^^^, V599E B-Raf mutant possesses 50-fold 
lower transforming activity in NIH3T3 cells than H-Ras^^^^ (Davies et al., 2002). 
This may reflect Ras signalling to a number of effector molecules. Three cell lines 
derived from human choroidal melanoma with BRAF乃舰 which showed 10-fold 
increase in endogeneous B-Raf activity activated Mek/Erk pathway constitutively and 
independent of Ras. However, inhibition of endogenous Ras significantly decreases 
cell proliferation rate, without affecting Mek/Erk activity (Calipel et al, 2003). 
Accordingly, cell proliferation resulted from BRAF mutation was only partially 
elevated, which could be further enhanced by parallel signaling pathway from Ras 
activation. 
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In melanoma, cell surface signaling by growth factor receptors through autocrine 
mechanisms is well established. Aggressive melanoma cells express both FGF and 
FGF receptor, forming an autocrine loop (Rodeck etal., 1991). Inhibition of this loop 
inhibited Erkl/2 phosphorylation (Kinkl etal, 2001). Melanoma cells also express c-
Met and secrete its ligand HGF. HGF also induces Erkl/2 phosphorylation through 
activation of its receptor, which can be inhibited by neutralizing antibody against 
HGF (Ll etal, 2001). 
Activating mutations in the kinase domain of B-Raf were detected in the majority 
of the melanoma cell lines with constitutively activated Ras without underlying 
mutations. Dramatic inhibition of Erkl/2 activation was observed when effects of 
FGF or HGF were neutralized. From these results, Satyamoorthy et al. (2003) 
proposed that melanoma growth, invasion, and metastasis are attributable to 
constitutively activated Erk apparently mediated by B-Raf kinase activation and also 
excessive growth factors through autocrine mechanisms. 
Autocrine or paracrine loops are also present in astrocytic tumors. The heparin 
binding epidermal growth factor-like growth factor (HB-EGF) is abundantly 
expressed in GBMs and is co-expressed with EGFR in 52% of GBMs. Anti-HB-EGF 
blocking antibodies reduced glioma cell growth by 30 - 40%. HB-EGF stimulation 
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efficiently induced glioma cell proliferation in vitro. Also, HB-EGF, FGF, or TGF 
stimulation rapidly induced HB-EGF expression (Mishima etal., 1998). 
TGF expression was found in 88% of GBMs (Maruno et al., 1991). Increased 
tumor growth in vivo caused by autocrine TGF stimulation was later shown to be 
mediated via EGFR activation, which was accessible to an EGFR specific tyrosine 
kinase inhibitor (El-Obeid et al., 2002). Hence, in the cases where EGFR expression 
IS normal, overexpression of wild-type B-Raf could also be stimulated by autocrine 
signaling to induce proliferation. 
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5.5. BRAF expression in astrocytic tumors 
Other than activating mutation, abnormal expression of an oncogene might also 
provide advantages to tumorigenesis. The possibility of such an effect of BRAF was 
supported by the observation of an increased number of mutant copies of BRAF in the 
cell lines GBM2603 and GBM6840. 
According to Dugan et al., B-Raf expression was absent in normal astrocytes. 
Indeed, B-Raf protein was not detected in astrocytes of specimens examined in this 
study. However, the same paper showed negative B-Raf immunoreactivity in human 
glioma U373 and rat glioma C6. Detection of BRAF mutation in the astrocytic tumor 
series brought up the necessity of clarifying B-Raf expression pattern in tumor 
specimens. My results not only showed positive B-Raf immunoreactivity in the 
mutant, but also revealed positive results in astrocytic tumors harboring 
wild-type B-Raf. Expression of the BRAF gene was detected in all grades of 
astrocytic tumors. The number of aberrant B-Raf expressing tumor cases did not 
increase with astrocytic tumor grade. 
Higher expression of B-Raf in astrocytic tumors than in normal astrocytes pointed 
to possible functional changes in favor of tumorigenesis. In neurons, activation of 
Erk by cAMP analogues in a Rap 1 /B-Raf-dependent manner rescued neurons from 
death (Dugan et al,, 1999; Vossler et al, 1997). On the contrary, cAMP decreased 
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Erk activity in normal astrocytes lacking the B-Raf protein. However, ectopic 
expression of B-Raf in rat astrocytoma cells increased Erk activation and enhanced 
proliferation in the presence of serum (Dugan et al., 1999). Accordingly, abnormal 
expression of B-Raf in astrocytes may restrain negative regulation of survival and 
proliferation, leading to tumorigenesis. 
In melanocytes, B-Raf also mediates activation of Mekl by cAMP. However, it 
is Ras but not Rapl which mediates the cAMP-dependent activation of Erk. The 
effect is also independent on Sosl and suggests the existence of a melanocyte-specific 
Ras exchange factor directly regulated by cAMP (Busca et al., 2000). Currently, it is 
not known whether a similar Ras exchange factor exist in astrocytes. 
B-Raf expression may play a tumorigenic role similar to BRAF mutation. 
Although wild-type B-Raf is dependent of Ras activation, an autocrine system could 
activate various effectors from Ras, including B-Raf. Furthermore, the effect of B-
Raf expression may not only as an additive to C-Raf activation. B-Raf and C-Raf can 
act co-operatively to produce synergistic effects in response to growth signals. Upon 
Ras activation, the COOH-terminus of C-Raf was exposed from 14-3-3 binding sites 
and constitutively associated with B-Raf (Weber et al., 2001). 
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5.4. Mutually exclusive pattern between EGFR amplification and BRAF 
expression 
As discussed in Section 5.2.2, Ras mutation is rare among astrocytic tumors. 
However, EGFR amplification in primary GBM could reach 50% (Figure 1.1) and the 
Ras protein has been considered as the downstream effector of EGFR, which relays 
signals to the MAPK cascade. Considering the mutually exclusive pattern of Ras and 
B-Raf in other tumor, it is interesting to investigate the correlation between EGFR 
amplification and BRAF mutation and the correlation between EGFR amplification 
and B-Raf immunoreactivity in astrocytic tumors. 
The investigation began with the determination of EGFR amplification in the 
astrocytic tumor samples involved in BRAF mutation screening. In the current series, 
EGFR gam was detected in 1 of 14 AAs (7.1%) and 2 of 24 GBMs (8.3%), whereas 
EGFR amplification was found in 1 of 14 AAs (7.1%) and 6 of 24 GBMs (25%). 
Frequency of EGFR amplification in the current study was found to be lower than in 
literature. 
In a previous study in our group, only a small proportion (17%, n 二 29) of primary 
GBM exhibited EGFR amplification while a high proportion (62%) showed either 
TP53 mutations or allelic loss of 17pl3.1 (Cheng et al., 1999). In this study, 
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frequencies of EGFR and TPJiabnormalities did not conform to the currently 
accepted models of GBM development which sub-classified GBM into primary and 
secondary ones. In Das et a/.,s study (2002), 7 of the 39 primary GBM samples (18%) 
available for DNA sequencing (7/39) had TP53 mutations, including three mutations 
previously undocumented m GBM. Therefore, frequencies oiEGFR amplification in 
primary GBM of Asian population may be lower than that in Western countries. 
Tumor progress of primary GBM in Asians may be more dependent on TP53 
mutations and other alterations other than EGFR amplifications. 
To increase sample size of tumors harboring EGFR amplification, 6 samples from 
another study were recruited in B-Raf immunohistochemistry and included in 
statistical correlations. As a result, three subtypes of astrocytic tumors were defined. 
They are tumors with EGFR amplification but negative B-Raf immunoreactivity, 
tumors with positive B-Raf immunoreactivity but no EGFR amplification and tumors 
harboring alterations in neither. Not considering the 6 addition samples which were 
included due to the presence of known EGFR amplification, the tumor group with 
EGFR amplification but negative B-Raf immunoreactivity constituted 25.0% (6/24) 
of the current series of astrocytic tumors. The second group, comprising of tumors 
with positive B-Raf immunoreactivity but no EGFR amplification, constituted 29.2% 
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(7/24) of the series. The remaining tumors harbor alterations in neither and 
comprised 45.8% (11/24). 
5.4.1. Similar effect of EGFR activation and B-Raf activation 
Both EGFR activation and B-Raf activation are related to vascular proliferation 
and dysregulation of apoptosis. On one hand, EGF activation of EGFR expressed on 
glioma cells resulted in enhanced secretion of VEGF by glioma cells (Goldman et al., 
1993). Both C-Raf activation and subsequent Mekl-dependent protection from 
extrinsic-mediated apoptosis are activated by VEGF, which are pivotal for endothelial 
cell survival during angiogenesis (Alavi et al., 2003). A role of EGFR amplification 
in dysregulation of apoptosis was given by monoclonal anti-EGFR antibody which 
promoted apoptosis while decreasing proliferation and VEGF expression. On the 
other hand, B-Raf was demonstrated as a critical signalling factor in the formation of 
the vascular system during development. BRAF knock-out mice possessed increased 
number of endothelial precursor cells, dramatically enlarged blood vessels and 
ap op to tic death of differentiated endothelial cells (Wojnowski et al, 1997). 
Indispensable of B-Raf in survival was demonstrated in explanted embryonic motor 
neurons and sensory neurons using knock-out mice (Wiese et al‘, 2001). 
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Overexpression of B-Raf confered resistance to apoptosis induced by growth factor 
withdrawal or PI3K inhibition (Erhardt et al, 1999). Suppression of B R A I ^ 5霞� 
human melanoma by siRNA caused growth arrest and promoted apoptosis. 
Possibly, blockage of apoptosis by B-Raf was through the Ra舰ek/Erk pathway 
because phosphorylation of caspase-9 by Erk was sufficient to block caspase-9 
processing and subsequent caspase-3 activation (Allan et al., 2003). This was also 
supported by a previous study in which the addition of cytochrome C to cytosols of 
cells overexpressing B-Raf failed to induce caspase activation (Erhardt et al.’ 1999). 
Therefore, B-Raf plays a role in dysregulation of apoptosis and a partial role in 
proliferation similar to EGFR amplification. 
5.4.2. Mutual effects between Ras/Raf/Mek/Erk and Akt signaling 
Activation of both the RaFMek/Erk and the Akt pathways are considered 
tumorigenic. Erk phosphorylates and activates several targets in growth control 
(Mandell et al, 1998). It may contribute to tumorigenesis by inhibition of apoptosis 
(Allan et al., 2003). It is highly activated in both low-grade and malignant gliomas 
(Besson and Yong, 2001; Shapiro, 2002). On the other hand, GBM cells expressing 
mutant PTEN contain high endogenous Akt activity and high levels of Ptdlns-3,4,5-
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Ps and PtdIns-3,4-P2. Deletion and/or mutation of PTEN are common in primary 
GBM (Section 1.2.3). Mutation of PTEN, which leads to high Akt activity，induces 
cell proliferation (Staal et al‘, 2002). Akt also inhibits apoptosis by leading to 
proteolysis of cyclin D and restraining p 2 1 w a f i the cytoplasm. LOH around PTEN 
IS closely associated with a reduced overall survival of GBM patients (Fan et al； 
2002). 
Spontaneously activation of EGFR resulted in constitutive phosphorylation of Erk 
but not members of the Akt pathway in the astrocytic tumor cell line SKMG3 
(Thomas et al., 2003). Nevertheless, the Ra£Mek/Erk and Akt pathways can be co-
operative. Inhibition of PI3K signaling with pharmacologic inhibitor or by the 
reconstitution of physiological levels of PTEN to dephosphorylate the lipid products 
of P13K negated the growth advantage imparted by EGFRvin (Klingler-Hoffmann et 
al., 2003). In human GBM cells, both introduction of wild-type PTEN and inhibition 
of EGFR decreased VEGF mRNA levels (Pore etal, 2003). 
Unexpectedly, phosphorylation of C-Raf by Akt inhibited the Ra£^Mek/Erk 
pathway in breast cancer cell line (Zimmermann and Moelling, 1999). Expression of 
Akt inhibited EGFR-induced B-Raf activity and inhibition of Akt up-regulated B-Raf 
in HEK293 cells (Guan et al., 2000). Although the contradictory role of Akt could 
not be explained presently, cross-talk between the Akt and the Ras/Ra£^ek/Erk 
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pathways at B-Raf suggested important role of BRAF alterations in tumorigenesis. 
Activation of the B-Raf protein by mutation and/or increased expression of B-Raf 
could disrupt the modulation of cell proliferation and the regulation of apoptosis. 
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5.5. Microsatellite analysis of chromosome 14q in human cancers 
LOH of chromosome 14q is common in a wide variety of tumors. These include 
lung adenocarcinoma, ovarian carcinoma, malignant mesothelioma, gastrointestinal 
stromal tumors, renal cell carcinoma, astrocytic tumors, neuroblastoma, meningiomas, 
nasopharyngeal carcinoma, colorectal carcinoma and head and neck squamous cell 
carcinoma (Figure 5.1). Four CRDs have been identified suggesting the presence of 
multiple TSGs. These regions are mapped, from the centromere to the telomere of 
the q arm, to 14qll.2 - ql3.1 (Rl), 14q23.2 - q24.2 (R2), 14q31.3 - q32.12 (R3) and 
14q32.2 (R4). 
Rl contains two consecutive regions with high LOH frequency. On one hand， 
CRDs of lung adenocarcinoma, malignant mesothelioma and gastrointestinal stromal 
tumors overlap in 14qll.2, a region centromeric form D14S80. LOH at the marker 
D14S283 m gastrointestinal stromal tumors reached 71% (El-Rifai et al., 2000). On 
the other, ovarian carcinoma and nasopharyngeal carcinoma possess CRDs 
overlapping in 14ql2, telomeric from D14S80. LOH at the marker D14S70 in 
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Figure 5.1. Chromosomal regions with high LOH frequency in human cancers. 
Thick Bars, chromosomal regions with frequent LOH; 
R, common region of deletions. 
a, Abujiang etal., 1998; b，Bandera etal., 1997; c，Bjorkqvist etal.’ 1999 and 
de Rienzo etal, 2000; d, El-Rifai etal” 2000; e，Schwerdtle etal” 1997; f, 
Hu etal, 2001; g, Hoshi etal” 2000 and Thompson etal” 2001; h, Simon et 
al” 1995 and Tse etal., 1997; i, Cheng etal., 1997 and Mutirangura etal., 
1998; i Bando etal,, 1999; k, Lee etal” 1997. 
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R2 locates on 14q24.1, which spans an interval of approximately 1.5 Mb. The 
tumors involved are malignant mesothelioma, gastrointestinal stromal tumors, renal 
cell carcinoma and astrocytic tumors. At D14S258, LOH was detected m 63% of 
gastrointestinal stromal tumors (El-Rifai etal., 2000). 
R3 is associated with malignant mesothelioma, astrocytic tumors, neuroblastoma, 
meningioma and nasopharyngeal carcinoma. While CRDs of astrocytic tumors and 
neuroblastoma span the whole region, meningioma showed LOH in markers 
centromeric from D14S68, malignant mesothelioma and nasopharyngeal carcinoma 
showed LOH in markers telomeric to D14S68. LOH was detected in 8 of 11 
informative meningioma cases at D14S48 and in 7 of 7 informative cases at D14S81. 
CRDs of malignant mesothelioma, astrocytic tumors, neuroblastoma and 
nasopharyngeal carcinoma extended to R4. 
R4 IS the smallest among the four CRDs. Nevertheless, it contains CRDs of at 
least nine tumors. They include ovarian carcinoma, malignant mesothelioma, renal 
cell carcinoma, astrocytic tumors, neuroblastoma, meningioma, nasopharyngeal 
carcinoma, colorectal carcinoma and head and neck squamous cell carcinoma. 
Other than the above four regions, a CRD in 14ql2.2 — q21.3 is singly discovered 
in head and neck squamous cell carcinoma. Thus, as many as 7 separate regions on 
14q are in potential of containing TSG. 
168 
5.6, Microsatellite analysis of chromosome 14q in astrocytic tumors 
In literature, two CRDs have been defined in astrocytic tumors. The first CRD, 
14q21.2 — q32.12, covers R2 and extends to R3 and the second region, 14q32.12 -
qter, overlaps with R3 — R4. The more centromeric CRD in astrocytic tumor, 
14q21.2 — q32.12 has undergone finer mapping in this study. This region overlaps 
with CRDs of renal oncocytoma (Schwerdtle et al, 1997), gastrointestinal stromal 
tumors (El-Rifai et cd., 2000), malignant mesothelioma (Bjorkqvist et al., 1999; de 
Rienzo et al, 2000), neuroblastoma (Hoshi et al., 2000; Thompson et al., 2001), 
meningioma (Simon et al., 1995; Tse et al, 1997), and nasopharyngeal carcinoma 
(Cheng et al, 1997; Mutirangura et al., 1998). It spans approximately 48.1 Mb, as 
revealed by a high-resolution genome-wide allelotype and CGH analyses (Hu et al, 
2001 and 2002). The region is defined between D14S288 and D14S280，which is 
derived from breakpoints of interstitial deletions detected in 2 diffuse astrocytomas 
and 3 GBMs. 
5.6.1. Finer mapping of common regions of deletion 
Microsatellite analysis was performed using 18 polymorphic markers located 
between D14S288 and D14S280 on chromosome 14q. Allelic loss was defined at 
loci with LOH value smaller than 0.6 or greater than 1.67. Tomlinson et al (2001) 
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advocated a critical allelic ratio of 0.5 for defining LOH. However, our samples 
were not microdissected. Endogenous endothelial cells were expected to be present 
among tumor cells. Also, in a number of studies, the critical allelic ratio for 
indication of LOH was defined to be 0.7 in non-microdissected sample. Therefore, a 
critical value of < 0.6 or >1.67 for LOH was considered appropriate m the present 
study. 
LOH in at least one locus was detected in 4 of 12 diffuse astrocytomas (33%), 2 
of 5 AAs (40%) and 3 of 13 GBMs (23%, including 1 of 2 GSs). These loci were 
considered to be the result of allelic loss rather than chromosomal gain, after 
consideration of CGH studies. Analysis of the 9 cases harboring LOH revealed 
interstitial deletion of chromosome 14q. Based on the overlapping deletion regions, 
four CRDs (Figure 5.2) were identified. 
CRDl spans a region of 3.3 Mb, flanked by D14S592 and D14S1026. CRDl 
contained two markers with high LOH frequencies (21.7% LOH in D14S997; 19.0% 
LOH in D14S592). It overlaps with CRDs identified in malignant mesothelioma, 
















































































































































































































































































































































































































































































































CRD2 spans an interval of 4.0 Mb between D14S1011 and D14S77. It overlaps with 
CRDs identified in neuroblastoma and the three tumor types just mentioned above. 
CRDS IS the smallest region and spans approximately 3.2 Mb between D14S43 and 
D14S59. It overlaps with CRDs identified in renal cell carcinoma and neuroblastoma. 
CRD4 covers 6.5 Mb between D14S1000 and D14S68 and overlaps with CRDs 
identified in neuroblastoma and meningioma. 
5.6.2. Genes within the common regions of deletion 
To search for potential TSGs within the CRDs, all referenced sequence genes 
within the CRDs retrieved from Human Genome Reference Sequence (Build 34, 
http://www.genome.ucsc.edu/) were evaluated. 
CRDl contains 14 referenced genes (Table 5.1). All except one have been 
reported in PubMed (http://www.ncbi.nlm.nih.gov/). One of them with high 
possibility of being tumor suppressor was protein phosphatase 2, regulatory suhunit 
B (B56), epsilon isoform (PPP2R5E). 
CRD2 contains 20 referenced genes (Table 5.2). Eighteen of them have been 
reported in PubMed. However, none of the genes revealed their identity as tumor 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Despite being the smallest CRD in the current study, CRDS (Table 5.3) contains 
64 referenced genes. Thirty-three of them have been reported in PubMed. Of note is 
the MLH3 gene which has been suggested to be a tumor suppressor. 
CRD4 contains three referenced genes (Table 5.4). Similar to CRD2, there is no 
information revealing their identity as tumor suppressors. 
Based on existing information, PPP2R5E and MLH3 harbor the potential of being 
tumor suppressors. Functions and evidences in support of being TSGs of the two 
genes were given below: 
PPP2R5E 
PPP2R5E encodes one of the protein subunits of protein phosphatase 2A (PP2A) 
which IS a major serine/threonine phosphatase for reversible protein phosphorylation 
m all eukaryotic cells and thereby, implicated in a variety of cellular function. PP2A 
IS related to the regulation of cellular metabolism, transcription, RNA splicing, 
translation, cell cycle progression, cell morphology and development. It is a 
structurally complex protein in which a single catalytic (C) subunit associates with a 
wide array of regulatory subunits termed variable subunits through a structural 
subunit A (Millward et al., 1999; Schonthal, 2001). Protein product of PPP2R5E 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Subunits A and C of PP2A are ubiquitously expressed as alpha and beta isoforms 
with highly conserved sequence. Subunit A acts as a scaffold protein for recruitment 
of variable subunits or other regulatory proteins. The variable subunits are classified 
into four families of unrelated proteins, the B，B，，B，，and B，，，family. Each family 
consists of a number of isoforms given by alternative splicing from one or more genes. 
In mammalia, the B subunit is encoded by four genes. Ba and B5 are widely 
distributed and Bp and By are highly enriched in brain. The B' family contains at 
least five distinct gene products in human. B 'a and B'y are widely expressed, and are 
extremely abundant in heart and skeletal muscle. B'p and B，5 are expressed 
predominantly m brain. PPP2R5E in 14q23.1 encodes the B，s subunit of PP2A, 
which IS a cytoplasmic phosphoprotein highly expressed in the brain (McCright et al., 
1996). The B，，family is consisted of PR48, PR59, PR72, PR130, which may be 
involved m the regulation of the Gl/S transition. Based on conserved epitope shared 
with the B' subunits, stratin and S/G2 nuclear autoantigen were identified as new 
members of a potential B，” subunit family. These variable subunits determine the 
substrate specificity, cellular and sub-cellular localization and catalytic activity of the 
holoenzyme (Janssens and Gods, 2001; Lechward etal., 2001). 
It has been suggested that the A subunit of PP2A is a tumor suppressor because 
gene encoding the Ap subunit was mutated in 15% of primary lung tumors and in 
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15% of colorectal carcinomas (Wang et al., 1998). Later, alterations in both Aa and 
Ap subunits were detected in a variety of primary human cancers such as breast 
carcinomas, lung carcinomas, melanoma (Calin et al., 2000), chronic lymphocytic 
leukemias (Zhu et al., 2001) and parathyroid adenomas (Hemmer et al., 2002). 
Recently, reduced expression of the Aa subunit of PP2A in human gliomas was 
detected by Western blot. However, only silent mutations in the Aa gene were 
detected (Colella et al‘, 2001). Site-directed mutagenesis studies revealed that N-
terminal mutants of Aa discovered in breast carcinoma are defective in binding B' 
but not B and B，，(Ruediger etal., 2001). 
According to Ruediger et al, the Aa and Ap subunit of PP2A are different in 
binding affinity toward subunit B and C (Ruediger et al., 2001). Notably, APC 
interacted with all assayed members of the B' family, whereas there was no 
detectable interaction with Ba, B", A, or C subunits. Also, p-catenin was 
specifically down-regulated by PP2A of the B' family (Seeling et al., 1999). PP2A 
subunit B' may, therefore, direct PP2A to dephosphorylate specific components of 
the APC-dependent signaling complex and inhibit Wnt signaling. 
Alteration of the tumor suppressor TP53 is common in malignancy. Cyclin G, 
whose mRNA expression does not change significantly during cell cycle, was 
demonstrated to be a transcriptional target of TP53 (Okamoto and Beach, 1994). 
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More recently, cyclin G1 and G2 were found to associate with a variety of B’ 
subunits and even interact directly with the catalytic C subunit without the A subunit. 
G2-PP2A complexes induced nuclear aberrations and hence Gl/S cell cycle arrest 
(Bennm etal., 2002). 
Negative role of PP2A is also linked to mitogenic signaling (Anderson et al., 
1990; Ugi et al., 2002; Zhou et al., 2002) and other aspects of cell cycle progression 
(Schonthal and Feramisco, 1993; Yan and Mumby, 1999;). However, the specific 
subunit was not clearly stated in those studies. 
PPP2R5E maps at chromosome 14q23.1 lay between D14S997，the locus with 
frequent LOH, and the flanking locus D14S1026 of the CRDl. Whether loss of 
PPP2R5E provides advantage to tumorigenesis awaits further refinement of CRDl 
and functional studies specific to the gene. 
MutL homolo2 3 (MLH3) 
DNA mismatch-repair is one of multiple replication, repair, and recombination 
processes that are required to maintain genomic stability in prokaryotes and 
eukaryotes. The isolation of E. coli strains with elevated frequencies of spontaneous 
mutations, contributed to the identification of four mutator genes that play central 
roles in mismatch-repair. They are MutS, MutL, MutH and MutU (Buermeyer et al., 
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1999). In human, expressed product of the homologs of bacterial MutL (MLH) forms 
various heterodimeric complexes with product of homologs of bacterial MutS (MSH) 
to mediate mismatch-repair (Jiricny, 1998). 
Muller A and Fishel R (2002) searched extensively for mutations in mismatch-
repair genes in HNPCC families and revealed that the majority of the alterations in 
MSH2 (40%) and MLHl (40%) genes constitute the majority of alterations among 
mismatch-repair genes, while mutation of other mismatch-repair genes are less 
common (5%). However, LOH in the chromosomal region containing MLH3 was 
detected in 30% of human colorectal cancers (Weber et al., 1999). Lipkin et al. 
(2001) definedMLH3 mutation in 6 tumors in screening of 36 colon tumors with high 
MSI Four of the mutations were biallelic inactivation of MLH3, suggesting that 
MLH3 IS a putative TSG. 
For gliomas, reports on MSI are conflicting. Zhu et al. (1996) found MSI in only 
3% of astrocytic tumors {n —- 33) using di-, tri- and tetranucleotide repeat 
microsatellite markers localized on chromosome 4 and 9, X, 13 and 22. Dams et al. 
(1995) showed MSI in 5 of 10 GBMs but not in 1 AA and 4 DAs using 17 different 
microsatellite loci over 7 different chromosomes. Four allelic shifts were defined in 4 
different GBM cases. The remaining showed an extra allele at two different loci. 
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The author concluded that MSI was a rather common phenomenon in gliomas, but the 
frequency of MSI in glioma was lower than that in HNPCC. 
In Leung et al.'s study (1998), MSI were detected in 3 of 17 (17.6%) GBMs and 1 
of 3 AAs. One of the GBMs with high MSI harbors germline and somatic mutation 
in the two alleles of the MLHl gene. The other two showed MSH2 mutation and 
somatic allele loss in tumor by sequencing. Since all patient donors of the tumors 
recruited in this study were aged 45 years or less, the author suggested that a 
proportion of primary GBMs in young patients could be caused by germline 
mutations of mismatch-repair genes. From this study, MSI might be more common 
among young patients and lead to contradictory results from different studies. 
Further study is required to investigate whether alterations in MLH3 was associated 
with subset of astrocytic tumors, especially within young patients. 
Due to the mismatch-repair function of MLH and MSH, MSI could be an 
indicator of alterations in these genes. However, MSI was detectable in less than 1% 
of nine markers (mononucleotide, dinucleotide and tetranuclotide) in a MLH3T mice, 
indistinguishable from wild-type fibroblasts (Lipkin et al., 2002). To test whether 
mutations in DNA mis match-repair genes cause an inherited risk of colorectal cancer, 
Liu et al. (2003) screened 70 patients suggestive of genetic predisposition for germ-
line mutations in MLH3. One frame-shift mutation and 11 missense mutations were 
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identified in 16 patients (23%). In one family, MLH3 mutation segregated with 
disease together with a missense mutation in MSH2. Interestingly, none of the tumors 
with MLH3 mutations showed MSI This suggested function other than mismatch-
repair of MLH3. In fact, MLH3 is involved in at least one other cellular function. 
Meiotic arrest and aneuploidy was detected in MLHST mice of Lipkin et al. (2002). 
Therefore, studies on MLH3 should not be limited to tumors with high MSI. Further 
studies are needed to investigate the functional role of MLH3 in tumor suppression, 
which may not be related to MSI. Further fine-mapping of CRDS is also required to 
evaluate whether MLH3 is related to astrocytic tumors. 
5.6.3. Overlapping deletion regions in astrocytic and non-CNS tumors 
Only two genes were discussed above despite four CRDs were defined because 
functional studies of the reference sequenced genes are far from completion. Some 
publications describe gene cloning without any functional work. Thus, little 
information is available for evaluation of functions in tumor suppression. Although 
no genes within CRD2 were regarded as a candidate in the mean time, this region 
overlaps with four other human cancers (Figure 5.2) which are included in R2, the 
region with the second highest frequency of LOH (Figure 5.1). 
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Studies on R2 are rather limited to renal cell carcinoma. In earlier FISH and 
microsatellite analysis of non-papillary renal cell carcinoma，a positive correlation 
between the frequency of 14q LOH and increasing grade (P < 0.001) and stage (P < 
0.001) of tumors were found (Herbers et a/., 1997，and Wu et al., 1996). Herbers et 
al. demonstrated recombination at chromosome 14q, which may lead to loss of one 
allele and duplication of the other. Combining data from Hu et al.'s study (2002) and 
the current studies, 34.5% of (n = 29) diffuse astrocytoma, 40% (n = 5) of AA and 
38.9% of GBM (34 GBM and two GS) showed LOH in at least one polymorphic 
locus on 14q. An increasing LOH frequency in increasing tumor grade was not found. 
More recently, chromosome 14q LOH was analyzed in clear cell renal cell 
carcinomas using three microsatellite markers (Mitsumori et al., 2002). One of them 
was D14S588 and the other two lay on 14q32.12 and q32.2 (both telomeric from 
D14S280). LOH was present in 35.4% of informative cases out of 130 cases at 
D14S588 and 39.5% for any one of the three markers. The proportion of cells with 
14q LOH was found to associate with tumor aggressiveness, implying the 14q LOH 
as a marker of latent metastatic potential in clear cell renal cell carcinoma (Mitsumori 
et al., 2002). Loss in D14S588 constituted 19.2% of astrocytic tumors in the current 
study, which is the marker with second highest imbalance frequency among the 14q 
markers used (except D14S1068). Whether these tumors, including three diffuse 
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astrocytomas, one AA and one GBM, with LOH in D14S588 possessed poorer 
prognosis or worse survival remained unknown due to limited clinical data. In 
Debiec-Rychter er a/.'s cytogenetic study, loss in 14q was also detected in two diffuse 
astrocytomas, both related to poor prognosis. 
Another study was on gastrointestinal stromal tumors (Gunawan et al., 2002). All 
tumors employed displayed clonal chromosomal aberrations; 15 were hypo- to near 
diploid, and four were near-triploid and hypotetraploid. The most common 
abnormalities detected were loss of chromosomes 14 and/or 22. It this study, loss of 
chromosome 14 and/or 22 was found to be early changes in gastrointestinal stromal 
tumorigenesis irrespective of site or differentiation. It cannot be predicted on whether 
the same tumor suppressor is shared by these stromal tumors and astrocytic tumors. 
However, the presence of 14q loss in diffuse astrocytoma revealed the abnormality is 
an early event. It is worth noting that Debiec-Rychter et al. detected total or partial 
losses of chromosome 14 in 11 GBMs, all of which were abnormal clones. 
CRD4, which is relatively large and also with no TSG candidates included, 
overlapped with CRDs in two other CNS tumors, neuroblastoma and meningioma in 
R3. In contrary to other tumors, abnormalities of chromosome 14 in meningioma 
contribute to a better prognostic stratification of patients at diagnosis. Multivariate 
analysis showed that tumor grade together with chromosome 14 status and age were 
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the best combination of independent variables for predicting relapse-free survival. 
Therefore, an oncogenic gene rather than a tumor suppressor may be present in R3. 
No hints on the position of the abnormalities on chromosome 14q were given in this 
study. In another study of meningioma, only 14ql3 and 14q32 were included. 
Benign non-recurring meningiomas were less likely to harbor 14q deletions than 
recurring cases (17% versus 50%, P = 0.013; Cai et al., 2001). Considering results 
from both studies, better prognosis may be limited to 14q LOH in R3. 
In summary, identification of tumor suppressors in the four CRDs awaits Rirther 
positional mapping and functional studies of genes within CRDs. More clinical data 
are also required to relate the CRDs with specific astrocytic tumor subtype. 
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6. Further studies 
6.1, Role of BRAF alterations in astrocytic tumors 
BRAF mutations have been detected in tumor specimens of various human 
cancers. However, BRAF mutation had only been revealed in glioma cell lines. In 
the current study, mutation and immunohistochemistry demonstrated BRAF 
alterations in astrocytic tumor specimens. These included a T1796A substitution in 
one GBM sample among a series of 24 diffuse astrocytomas, 17 AAs and 53 GBMs, 
and B-Raf immunoreactivity in 31.9% of an astrocytic tumor series consisting of 25 
GBMs, 13 AAs and 9 diffuse astrocytomas. Although mutation of the BRAF gene is 
rare among astrocytic tumors, sequencing and karyotyping analyses indicated 
increased copies of BBAF^^e ^^  two additional GBM cell lines. These results 
suggest that B-Raf plays a role in the tumorigenesis of astrocytic tumors. The exact 
tumorigenic role of B-Raf in astrocytic tumor remains to be clarified. Therefore, an 
investigation on the biological effect of wild-type and V599E B-Raf expression was 
proposed. 
To investigate the functional effects of B R A F 而 
on astrocytic tumors, foil 
length BRAF cDNA containing the V599E mutation can be obtained by reverse 
transcription-PCR of our cell lines, for example, GBM2603. The PCR products can 
then be digested with restriction enzymes and cloned into mammalian expression 
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vector. Next, BRAF^^^^^-hmhoxmg vectors and vectors without gene insert can be 
used to transfect GBM cell lines without B-Raf expression. Functional assays of 
V599E transfected cells could then be compared with control cells with respect of 
proliferation and apoptosis. 
In contrast to other tumors derived from B-Raf-expressmg normal tissue, 
expression of wild-type B-Raf was seen in astrocytic tumors but not in normal 
astrocytes. To determine the functional effect of wild-type B-Raf on astrocytic 
tumors, transfection of the same GBM cell line with full-length wild-type BRAF 
cDNA is also to be performed. This also enables the comparison of the functions of 
wild-type B-Raf with those of V599E B-Raf mutant. 
To further investigate the functional effects of wild-type and mutant BRAF on 
tumorigenesis, the transfection experiments described above could be complemented 
by loss-of-function experiments in cell lines. Functional inactivation of BRAF gene 
by siRNA is regarded as an efficient and specific method in reducing B-Raf protein in 
tumor cell lines. Any reduction in proliferation or increase in apoptosis resulted from 
stable suppression of B-Raf expression can provide strong evidence for the roles 
being played by wild-type and V599E mutant ^ iMF in astrocytic tumors. 
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Moreover, wild-type BRAF- and mutant ^TMF-transfected tumor cells and/or 
suppressed GBM cells could be transplanted into nude mice so as to examine the in 
vivo tumorigenecity of wild-type and mwtmt BRAF in astrocytic tumors. 
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6,2, B-Raf expression in astrocytic tumors and correlation with EGFR over-
expression 
As stated before, immunohistochemistry revealed B-Raf expression in astrocytic 
tumor specimens but not in normal astrocytes. Positive B-Raf immunoreactivity was 
detected in about one-third of astrocytic tumors. This suggests a selective growth 
advantage provided by the B-Raf protein. However, immunoreactivity has not 
revealed the level of B-Raf expression in tumor cells examined. A precise 
quantification of B-Raf expression from diffuse astrocytoma to GBM is 
recommended for evaluation of the significance of BRAF in tumor development. For 
accurate quantification of B-Raf expression, a reverse transcription real-time PCR is 
suggested. Correlation analysis between B-Raf expression level and tumor grade can 
be performed. 
Moreover, about 20% of primary GBM without EGFR amplification also 
overexpress EGFR (Kleihues and Cavennee, 2000). The B-Raf expression status in 
EGFR-overexpressing tumors which do not harbor EGFR amplification has not been 
studied. For correlation analysis between EGFR expression and B-Raf expression, 
quantification of EGFR expression by reverse transcription real-time PCR in the same 
series of tumor samples is proposed. 
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6.3. Microsatellite analysis of 14q in astrocytic tumors 
Microsatellite analysis in 14q21.2 — q32.12 defined 4 CRDs. Each of the CRDs 
overlaps with CRDs in other tumors. However, none of them is small enough to 
propose a putative TSG. Therefore, more polymorphic markers within the CRDs are 
required for finer mapping of tumor suppressor loci. 
Moreover, since more than one CRD is present on 14q, more samples are to be 
recruited in future for finer mapping of CRDs. Also, a larger sample size is more 
representative in reflecting the actual frequency of LOH on 14q. In this study, overall 
allelic loss was detected in 9 of 32 astrocytic tumors (28%), a frequency lower than in 
the previous whole-genome allelotype study of Hu et al, 2002 (GBM, 50%, n = 21; 
diffiise astrocytoma, 35%, n = 17). Discrepancy in LOH frequencies is likely 
attributed to the use of small sample size in both of our studies. Furthermore, the use 
of adequate samples with clinical data may reveal the pattern of CRDs in 14q of 
astrocytic tumors in relation to survival and prognostic parameters. 
Furthermore, the study of Hu et al. (2002) defined 2 CRDs m 14q of astrocytic 
tumors. The present study only included fine-mapping of the more centromeric 
region. Fine mapping is also to be done for the more telomeric one. 
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7. Conclusions 
BRAF^麗 mutation was detected in one of 53 GBMs but not in 24 diffuse 
astrocytomas, 17 AAs, 31 oligodendroglial tumors, 23 ependymal tumors, 21 MBs 
and 25 meningeal tumors. These results indicate that BRAF mutation is a rare event 
m CNS tumors and is limited to GBM in the series examined. 
BRAF^麗 mutation was also detected in GBM2603 and GBM6840 of 10 CNS 
cell lines (6 from astrocytic tumors, 3 from MBs and 1 from PNET) examined. Both 
of which are derived from GBM. Karyotype analysis showed increased copies of 
chromosome 7 and sequence electropherograms displayed stronger signal of mutant 
BRAF allele than wild-type allele in both GBM2603 and GBM6840. Therefore, a 
preferential increase in copy number of BRAF刚呢 exists in the GBM cell lines. 
Elevation of BRAF^^^^^ copies in cancer cells is a novel finding. Together, these 
results suggest that both sequence alteration and enhanced copy number of mutant 
BRAF allele are involved in the development of GBM. 
B-Raf expression in normal astrocytes was undetectable by 
immunohistochemistry. However, B-Raf expression was detectable in about 30% of 
astrocytic tumors. Elevated B-Raf expression was found in WHO grade H to grade 
IV astrocytic tumors. The abnormal expression of wild-type B-Raf protein in the 
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low-grade diffuse astrocytoma suggests that BRAF alteration occurs early in the 
tumorigenesis of astrocytic tumors. My results are in line with those observed in 
melanoma (Pollock etal., 2003), supporting the notion that B-Raf is involved in early 
stages of tumorigenesis. 
Because B-Raf is a downstream effector of the EGFR pathway and EGFR 
amplification is a common genetic alteration seen in GBM. I therefore examined the 
relationship between BRAF mutation and EGFR amplification in a GBM series. My 
data showed that the BRAF^^^^^-contmmng GBM, BJIO, did not harbor EGFR 
amplification. This result suggests that BRAF mutation and EGFR amplification are 
mutually exclusive events. However, such relationship should be verified in a larger 
series. Furthermore, I also investigated the relationship between B-Raf expression 
and EGFR amplification. Of the 30 astrocytic tumor specimens tested, EGFR 
amplification and B-Raf expression were mutually exclusive. Tumorigenic effect of 
wild-type B-Raf which is incapable in self-activation was thought to be sustained by 
autocrine or paracrine stimulation. 
Taking together, my data demonstrated that BRAF can be altered both in the gene 
level and in the transcription level, and such alterations play an important role in the 
tumorigenesis of astrocytic tumors. 
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Other than examining BRAF alterations among CNS tumors, the current study 
also included fine mapping of a CRD located m the long arm of chromosome 14 of 
astrocytic tumors. In a previous allelotype analysis on difiEiise astrocytoma (fibrillary) 
and GBM, two CRDs were located to 14q. The second aim of the current study is to 
fine map the more centromeric CRD, which is located in 14q21.2 — q32.12. Using 18 
polymorphic markers, this region of 48.1Mb was found to contain four separate 
CRDs. The new four CRDs within 14q21.2 — q32.12 span approximately 3.3Mb, 
4.0Mb, 3.2Mb and 6.5Mb, respectively. All of them overlap with those of other 
cancer types. This indicates that fiinctional inactivation of one or more shared TSG 
contributes to their etiology. Based on current knowledge on the candidate genes 
annotated m the CRDs, PPP2R5E and MLH3 may be putative TSGs within two of the 
four regions and worth further characterization. However, these regions are still 
considerably too large for positional cloning of candidate genes. Further refinement 
of the CRDs followed by characterization of the target TSGs will enhance our 
understanding of tumorigenesis of astrocytic tumors. 
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